BIOTECH IN EUROPE INVESTOR FORUM

Transcription

1 BIOTECH IN EUROPE INVESTOR FORUM 30th September 1st October 2013 Hilton Zurich Airport Hotel, Switzerland Conference Guide I N SUPPORTING ORGANISATIONS B I O T E C H PRESENTING COMPANIES E U R O P E SPEAKERS I N V E S T O R F O R U M WELCOME 13th Annual

2 Welcome Sachs Associates are delighted to welcome you to the: 13th Annual Biotech in Europe Investor Forum 30th September-1st October 2013 Hilton Zurich Airport Hotel, Switzerland Sachs Associates are delighted to welcome you to the 13th Annual Biotech in Europe Investor Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe s Biotech industry. The programme highlights the current issues surrounding the evolving M&A market, the Private Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year s programme features more than 80 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners. General Information The registration desk will be open from 8am on September 30th and from 8am on October 1st although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session. Networking at the Forum is facilitated by our online meeting system, which is available to all participants. A Networking Lunch will be set up in the Zurich A & B rooms. Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the event. Request for Presentations Please use the agenda to mark off presentations that you are interested in and your request to Sian@sachsforum.com after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference.

3 Events Diary For regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events please contact Sian Rodgers on MedTech & Diagnostics Innovations Summit 21st November 2013 Düsseldorf Germany The Summit is being held to coincide with the leading annual international tradeshow Medica with its 135,000 visitors and is designed to bring together a specialist audience from leading and growth companies focused on M+A, alliances and Investment. The program will feature keynotes from industry leaders and plenary panels on industry acquisitions; public markets, venture investment and growth, company finance, and diagnostics. The subjects of regulation and reimbursement will also be covered. Apart from the plenary session the program will also feature 20+ public and private company presentations focused on innovation and alliances/investment opportunities. The MedTech & Device and Diagnostics presenting track will cover: Oncology, Cardiovascular, Imaging, Digital Healthcare, Surgical Devices & Implants and Diagnostics. There will be many networking opportunities. There is a 1-to-1 online meeting system with meeting rooms provided. In addition, there will be networking breaks and a conference cocktail reception. Participation will be limited and presentations by invitation. Financial Investors will receive complimentary passes. We plan an audience of delegates. 7th Annual European Life Science CEO Forum For Partnering & Investing 4th 5th March 2014 Zurich Switzerland Back for its seventh year, this exclusive and highly transactional partnering event is a must for companies wishing to meet with their peers, engage with leading investors and forge new partnerships. Building on the success of this year s event, the forum will provide an excellent platform to gain insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the Forum is facilitated by our online meeting system, which is available to all participants. The conference will feature up to 80 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners. Do not miss out on this great opportunity to meet emerging companies, leading global investors and Big Pharma representatives! 14th Annual Biotech in Europe Investor Forum 7th 8th October 2014 Zurich Switzerland

4 Speakers Alain Huriez, Venture Partner, Advent Venture Partners & Chairman, EPEMED Alain joined Advent in 2012 bringing 22 years of experience in management, drug development and financing in the life sciences sector, including CEO of TcLand Expression and Neovacs, Associate Partner at Truffle Capital and Vice President at Quintiles. Alain is a medical doctor and holds an MBA and a Masters of Pharmaco-Economics from Paris La Sorbonne University. Prior to joining the industry, he was head of the emergency room in a large teaching hospital and practiced as a General Practitioner for two years. Alain has been responsible for several initiatives in Europe within the areas of personalized medicine, biomarkers and high value diagnostics through his work as chairman of EPEMED, the European Personalised Medicine Association he founded in As an entrepreneur, he co-founded four French biotechnology companies. Prof. Dr. André Rosenthal, CEO, Signature Diagnostics AG André Rosenthal is founder and CEO of Signature Diagnostics AG, a cancer diagnostic company focused on prognostic and predictive (companion diagnostic) biomarkers in colorectal cancer. The biomarker research of Signature is based on a large prospective, multicenter clinical diagnostic study in colorectal cancer which has recruited more than patients of all four UICC stages. Fresh-frozen, FFPE tumour tissue specimens and plasma samples with longitudinal clinical annotation are used for deep sequencing with the aim of developing accurate tumor tissue and plasma based tests. André s current interest is translational oncology with a focus on developing novel next generation sequencing (NGS) tests based on circulating free DNA from plasma which can be used for monitoring colorectal cancer patients but also for early detection of colorectal cancer. In addition, we develop NGS tests for the prediction of outcome (prognosis) of colorectal cancer patients and for the prediction of response to treatment. Signature Diagnostics has developed a suite of five NGS tests in these indications. Our plasma test OncoDetect is an ultra deep sequencing test if circulating DNA and can be used for monitoring patients with colorectal cancer of stage III and IV. This test was presented at the recent ASCO 2013 meeting. Our prognostic NGS test OncoSelect-III will be presented at the 17th ECCO meeting in September 2013 in Amsterdam. Between André was a member of the core team involved in the world wide Human Genome Sequencing Project (HUGO), from in Cambridge (UK) with Sydney Brenner and John Sulston, from 1993 in Germany as a professor at the Friedrich Schiller University in Jena (Germany). He was in charge of the German Human Genome Sequencing Project and led the chromosome 21 sequencing project in collaboration with Japanese researchers. His team in Jena also contributed to the sequencing of human chromosome 8 and X. During he participated in several positional cloning projects of human disease genes including X-linked hydrocephalus, MASA syndrome and X-linked spastic, paraplegia (CRASH syndrome), Turner syndrome, Nijmegen breakage syndrome, tricho-rhino-phalangeal syndrome type I, X-linked congenital stationary night blindness, X-linked retinitis pigmentosa 2, MALT lymphoma, and others. André has authored or co-authored 135 peer reviewed original papers. He is an inventor of many patents and patent applications. Anja König, Managing Director, Novartis Venture Fund Anja is active in Switzerland and Europe and also responsible for expanding the fund s presence to Asia Pacific. Prior to joining Novartis she was an Associate Partner at McKinsey and Company, a global consultancy, where she worked with companies in health care in the US, Europe and Emerging Markets. Anja König is a scientist by training and holds a PhD in physics from Cornell University. Anja serves on the boards of Bicycle, Covagen, Heptares, F2G and Nabriva and works with Destiny, Neomics, Oxagen, PharmAbcine, Polyphor and Qurient Therapeutics.

5 Speakers Bart Wuurman, CEO, Lanthio Pharma BV Bart Wuurman, PharmD, has 25 years of International Pharma and Biotech Industry experience. He gained broad industry experience, ranging from drug development, product licensing to General Management and fund raising with Organon, Medeva, Antisoma, DeNovo Pharmaceuticals and AM-Pharma. He was instrumental to raising around e40 million VC financing and to closing licensing deals worth e700 million. Bart has been a biotech CEO for 11 years, in the UK and in the Netherlands. Bart joined Lanthio Pharma as CEO in He holds pharmaceutical sciences degrees from Dutch Universities in Utrecht and Leiden. Bernd Goergen, Senior Investment Manager, High-Tech Gründerfonds Management Since 2008, Bernd Goergen, Ph.D. works for the High-Tech Gruenderfonds (HTGF) as Senior Investment Manager. The biologist and DVFA-certified Biotech analyst combines 5 years of research experience in virology-immunology and in-depth expertise from 7 years ( ) international diagnostics marketing for global market leaders in Germany and the US. Between 2000 and 2007 he joined the investment banking department of a major German bank, where he organised M&A activities and capital market transactions like IPOs and capital increases for life science companies. Bernd currently manages a portfolio of 14 companies for HTGF with a split between medical devices and pharma/biotech. He also serves as a board member in 4 of the funds life science firms. Dr Bernd Muehlenweg, CBO, Nanobiotix Bernd holds a doctorate in chemistry from the Technical University of Munich, extended by management training at the St. Gallen Business School, as well as several merger/acquisition and negotiation techniques seminars. He was responsible for several negotiations and the execution of several licences and marketing contracts. Mr Muehlenweg is co-author of more than 17 publications and 2 patents. He is member of the Pharma Licensing Club of Germany. Before joining Nanobiotix Bernd was Business Development Director for Wilex AG in Munich, where he made significant contributions to position Wilex as a leader in the market of development of therapeutic molecules and diagnostic tools in oncology. He joined Nanobiotix in 2011 where he is responsible for ensuring the sustainable growth of the Company by concluding strategic alliances with partners. Beth Jacobs, Managing Partner, Excellentia Global Partners Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank, founded in Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the corporate sector. Prior to 2008, Beth was a partner at Bio-IB, a life sciences investment bank based in New York, as Managing Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she founded and led its international institutional equity group for over 7 years. She started her career at Prudential Securities where she founded the international institutional equity business, and later headed the same product execution group at both Morgan Stanley and Lehman Brothers. She currently serves on the Board of Directors of EF Foundation, a global educational services company based in Stockholm and Cambridge, Mass, Board of Governors of the New York Academy of Sciences, founding Global Ambassador for Susan G. Komen for the Cure, Board member for both the Harvard Kennedy School of Government Women s Leadership Board and as Vice Chairman of the Board for the Budapest Festival Orchestra. Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of Foreign Service, and a BA, cum laude, from Boston College. She also studied at Centre d Etudes Internationale in Geneva, Switzerland.

6 Speakers Carlos Buesa, CEO, Oryzon SA Carlos is a specialist in the Biotech Industry. Dr Buesa got his PhD in Biochemistry and Molecular Biology from the University of Barcelona, Spain in He was post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and later Senior Investigator at the Flemish Institute of Biotechnology (VIB). Back in Spain, in 2000, he founded Oryzon. Since inception he has served as Chief Executive Officer and Chairman of the Board of Directors. Under his leadership the company has got +14M euros in several funding rounds and the company has evolved from a genomics based company to a clinical company with its first program in Epigenetics in Oncology in Phase I/IIA. He has taken the executive education programme (PADE) at the IESE Business School in Barcelona and several additional educational programs in finances, negotiation skills, international commerce and advanced business development He is now board member of the Spanish Association of BioIndustry (ASEBIO), VicePresident of the Association of Catalan Biotechnology Companies (CataloniaBio), and he was also member of the Executive Committee of BioRegió de Catalunya, a regional biocluster body that has been set up with the aim of improving of the biotechnology sector in Catalonia. In addition, he sits on the board of other biotech companies like GEADIC Biotech, PaloBiofarma, Neurosciences technologies, NINFAS Biotech and Oncnosis Pharma. He is also board member in the VC-seed firms Inveready seed and Inveready Biotech. Carole Nuechterlein, Head, F. Hoffmann-La Roche AG Roche Venture Fund Carole Nuechterlein has headed the Roche Venture Fund since Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals. She currently serves as a board observer at Aileron, Alios, Ambrx, BioFire Diagnostics and Epic. She has a BA from Valparaiso University and a JD from University of Michigan. More information on the Roche Venture Fund can be found at Chris Britten, Head of Business Development, Sanofi Pasteur-MSD Chris is currently Head of Business Development at Sanofi Pasteur-MSD with responsibility for all business and corporate development activities. Sanofi Pasteur-MSD is a Joint Venture between Sanofi Pasteur and Merck & Co. and is focused on the development and commercialisation of vaccines in Europe. Chris is also the Managing Director of Vantage Life Sciences, offering strategic and transaction advisory services to the life science sector. Chris joined Sanofi Pasteur-MSD in 2013 following positions at Astellas (Europe) in Business and Commercial Development and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising). Prior to Deloitte, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate Ventures and R&D. Chris holds a PhD in Biochemistry and an MBA in Finance.

7 Speakers Chris Maggos, Alpine Institute for Drug Discovery Chris has 20 years of experience in the life sciences industry covering business development, investor relations, communication, investing and molecular neurobiology. Most recently, Chris has been working to establish the Alpine Institute for Drug Discovery, a social enterprise focused on translational drug discovery of novel immunotherapeutics via open innovation. Prior to launching AIDD, Chris was a member of the executive management board at Addex Pharmaceuticals and held the positions of head of investor relations & communication ( ) and director of business development ( ). Previously he worked as: a journalist for the biotechnology trade publication BioCentury ( ); an investor at a NYCbased biotechnology hedge-fund ( ), called Casdin Life Science Partners (later called Cooper Hill); and a molecular neurobiologist studying drug dependence at The Rockefeller University ( ). He is co-author on 12 peer-reviewed publications. Chris holds a BA from Yale University in English Literature (where he also completed pre-medical studies). Christina Takke, Partner, Forbion Capital Partners Christina holds a PhD in Developmental Biology, which she obtained under the supervision of Prof. Dr. Campos-Ortega at the Institute of Development Biology of the University of Cologne. As an undergraduate Christina studied Molecular Biology/ Biochemistry at the Technical University of Darmstadt, Université de Bordeaux and at the Institut National de la Recherche Agronomique (INRA) Montpellier. After her studies, she gained experience in working with biotech startup companies at Bio-Gen-Tec-NRW in Cologne, Germany, a regional development organization for the biotechnology industry. She evaluated business proposals and assisted the young biotech companies in the fundraising process. Christina joined the ABN AMRO Capital Life Sciences team as an analyst in Following this assignment she became Principal before being promoted to Partner. At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as general deal execution. Christina currently serves on the supervisory boards of Forbion s portfolio companies Amakem NV, argen-x BV, and Pieris AG. In recent years she served on the board of Bioceros, and she was closely involved with GlycArt AG as a Board Observer (sold to Roche in 2005). Corinne Savill, Head Business Development and Licensing, Novartis Pharma AG Corinne has over 15 years of broad experience in both the pharmaceutical and biotech arena. In her current position, she has responsibility for all Business development and partnering deals within Novartis. After a Ph.D. in Immunology and a number of academic and pharmaceutical research positions, Corinne joined Imutran Ltd a UK based Biotech as Director of Research. In 1996 Imutran was acquired by Novartis and Corinne made the COO. She moved to Basel in 2001 as the CEO of the Novartis Bio Venture Fund, managing a CHF 100 million investment account and establishing a new network for Novartis with venture capital companies in the US and Europe. Corinne then moved to the Transplantation and Immunology Business Unit as Regional Manager, Western and Central Europe, where she was in charge of 11 regions and countries. In 2005 Corinne moved to head up Global Search and Evaluation with Novartis Business development where she was responsible for the identification and evaluation of potential license-in or M&A opportunities, growing the Novartis development pipeline and supporting the business goals of Novartis. In 2010 Corinne became Novartis s Global Head of Pricing and Market Access responsible for the pricing and market access strategies for the entire portfolio of Novartis Pharma s development and in Market products world-wide. In June 2013 Corinne was appointed Head Business Development and Licensing Novartis Pharma AG. David Pinniger, Fund Manager, Polar Capital David joined Polar Capital in August 2013 as a fund manager within the healthcare team. He has over 12 years investment experience in the healthcare sector. Prior to joining Polar Capital, David was a portfolio manager of the International Biotechnology Trust at SV Life Sciences. He also previously spent three years working at venture capital firm Abingworth as an analyst managing biotechnology investments held across the firm s venture and specialist funds, and four years at Morgan Stanley as an analyst covering the European pharmaceuticals and biotechnology sector. He is a CFA Charterholder.

8 Speakers David Urech, Co-CEO, CSO, Numab David studied Molecular Biology and Neurosciences at the University of Zurich, where he received his master degree in He then joined Prof. Howard Riezman at the Biocenter of the University of Basel where he completed his Ph.D. in Biochemistry in As a Senior Scientist at Esbatech, David led the antibody discovery group and became Head of Research & Development and member of the Senior Management in In this position he was responsible for the definition of the scientific strategy, evaluation of drug targets and the positioning of Esbatech s platform technology. He transformed an initially 5-people discovery team into an integrated Research & Development unit consisting of 30 employees. This unit covered activities from technology development through antibody discovery and preclinical development. During his time at Esbatech, David developed a novel discovery platform, which reproducibly gives rise to highly potent and stable antibody fragments. Further, his seeding scientific work on the pharmacokinetic properties of antibody fragments enabled the development of Esbatechs TNF-inhibitory scfv that became the first antibody fragment to be successfully applied topically by eye drops in a clinical setting. The technologies and products developed by David and his team turned out to be the value driving factor for Esbatech s acquisition by Alcon in September Most recently ESBA1008, an antibody fragment developed by David s group entered a clinical phase 2 trial. David is an inventor of over a dozen patent priority applications and his scientific work has been published in numerous peer-reviewed journals. Deborah Harland, VP & President, SR One Deborah joined SR One in 2005 to establish the firm s European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 20 year tenure in the pharmaceutical industry. Deborah is currently a member of the Board of Directors of Mission Therapeutics Limited, Protaffin AG, Bicycle Therapeutics Limited, Syntaxin Limited, and f-star GmbH. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College. Dirk Beher, Chief Scientific Officer, Asceneuron SA Dirk is a founder of Asceneuron SA and joined the company as Chief Scientific Officer at its inception. He led the spin-off proposal for Merck Serono s Alzheimer s disease portfolio and successfully raised EUR 5M seed funding which materialized in the creation of Asceneuron SA in October Dirk has more than 21 years of experience in the field of Alzheimer s disease and spent over 15 years in pharmaceutical drug discovery. Prior to Asceneuron he has held various positions with increasing responsibility at major pharmaceutical and biopharmaceutical companies in worldwide geographical locations. Previously, Dirk was the director of the Alzheimer s and Parkinson s Neurobiology Unit at Merck Serono in Geneva, Switzerland. He was responsible for the strategic build-up of Alzheimer s disease as a new indication and implemented the project portfolio which represents Asceneuron s pipeline. Prior to Merck Serono Dirk worked in the Neuroscience Department at Amgen Inc. in Thousand Oaks, California where he managed the in vitro pharmacology team and oversaw a diverse CNS portfolio as management team member. Dirk started his career in pharmaceutical drug discovery by joining Merck Sharp & Dohme (Merck & Co.) in Harlow, United Kingdom in During that time he made key contributions to the clinical γ secretase inhibitor MK-0752 and was finally responsible for all γ secretase programs. Dirk holds a Ph.D. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor of seven patents and currently authors 47 peer-reviewed publications and reviews.

9 Speakers Douglas M. Fambrough, CEO, Dicerna Pharmaceuticals, Inc. Douglas is a co-founder of Dicerna Pharmaceuticals and joined the company as CEO in May Prior to joining Dicerna, Dr. Fambrough spent over a decade as a biotechnology venture capitalist with Oxford Bioscience Partners, one of Dicerna s investors. At Oxford, he specialized in financing innovative life science technology companies such as the first generation RNA interference company, Sirna Therapeutics (acquired by Merck). Among his other investments are high-throughput DNA sequencing pioneer Solexa (acquired by Illumina); Xencor, which engineers antibody Fc domains to enhance drug properties; Rib-X Pharmaceuticals, a developer of antibiotics against multi-drug resistant pathogens; and Solstice Neurosciences (acquired by US WorldMeds). Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). Dr. Fambrough graduated from Cornell University and holds a Ph.D. in genetics from the University of California, Berkeley. Dr Edward D. Blair, Managing Director, Integrated Medicines Ltd Dr Edward D. Blair is Managing Director of Integrated Medicines Ltd (IML), a company he formed in 2003 to enable personalised medicine by combining diagnostic-type testing with new and existing medicines. He is also Chief Executive of Integrated Magnetic Systems Ltd (IMSL), a non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, and a visiting scholar to the Cambridge University Masters in Bioscience Enterprise programme. He also lectures on personalised medicines and offers occasional bespoke courses based on his best-selling books. Eddie has published more than 40 primary, peer-reviewed papers, including a series on companion diagnostic valuation, and is editor of two personalised medicine journals. Finally, he is named inventor on at least one dozen patents, including tuneable magnetic proteins, the technology being exploited by IMSL. Elena Startseva, Head of Business Development, OCT Clinical Trials As a Head of Business Development, Elena is responsible for new business opportunities assessment and management; she supervises OCT s advertising, client relations and budget negotiations. She manages development of OCT general capability presentations as well as study specific presentations to clients from all over the world. Elena has started working in the Pharmaceutical/CRO industry in 2005 as a CRA and has a deep knowledge and expertise in the field of clinical research. Prior to joining the OCT team, Elena worked for Quintiles GesmbH as a Clinical Study Manager. After several years of experience as a Senior Project Manager at OCT, Elena has been appointed to lead the Business Development team. Elena holds Doctor of Medicine degree from the St. Petersburg Peadiatric Medical Academy, she completed residencies in forensic and general pathology, and an MBA degree in International Business from Stockholm s University. Eric Halioua, MBA, Co-Founder and CEO, Promethera Biosciences Eric Halioua is the CEO and co-founder of the Belgian Biotechnology company Promethera Biosciences. Promethera Biosciences mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using stem cell from healthy human livers. He is as well Board members the biotechnology company Bioxodes, the European Biopharmaceutical Enterprises (EBE) and of the Belgian Walloon region Biocluster (BioWin). Eric is co-founder of two biotechnology companies called Myosix and Murigenetics. Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been sold to Genzyme mid Murigenetics is a Biotechnology company developing therapies for genetic disorders. Eric was also a Board Member of a French public biotechnology company called Vivalis, which specializes in the production of avian stem cells lines for the production of vaccines and recombinant proteins. Eric was as well principal of the international life sciences practice of Arthur D. Little based in Paris and Boston during 11 years. He has led work in the areas of strategy, M&A and technology & innovation management for biotechnology and pharmaceutical companies. Eric also worked as a strategic marketing manager for the Centre Européen de Bioprospective and as project leader in the corporate R&D centre of Zeneca in UK. Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

10 Speakers Eric Massou, CFO, Poxel Pharmaceuticals Eric Massou has 19 years experience as an external auditor at Mazars and Ernst & Young, where he was mainly in charge of industrial groups such as Becton Dickinson, Black & Decker, Brenntag or Candia. Eric acquired experience as a financial controller and group CFO at Veriplast Packaging, a plastic packaging company operating in 7 European countries. There, he was involved in all recurrent financial aspects and monitored two major vendor due diligence projects to welcome Charterhouse in 2004 and SUN in 2007 as new shareholders. In addition, Eric was on the deal team for all M&A activities and in charge of external stakeholders, and he raised all necessary new monies to support business growth and finance new industrial capex. Eric received a Master in Finance at EM Strasbourg, the BESS program of Trinity College Dublin (Ireland) as well as the French CPA. Eric joined POXEL in January Esteban Pombo-Villar, Chief Operations Officer, Oxford BioTherapeutics Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in At Sandoz he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry. Dr Fintan Walton, Chief Executive Officer, PharmaVentures Ltd Dr Walton is the Founder and CEO of PharmaVentures. He was educated at the University of Michigan (US) and Trinity College (Dublin, Ireland), and subsequently he gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc ( ). As an entrepreneur, Dr Walton co-founded CONNECT Pharma in 1992, a company focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making including strategic alliances, Mergers & Acquisitions and equity financing. In 1997 the company became PharmaVentures. His company has worked with blue chip clients on a global basis, delivering more than 600 assignments for companies in 37 countries. Clients have included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device, generic and OTC companies. His clients have also included major banks, investment/merchant banks, and private equity and venture capital groups. Although Fintan s main focus is his role as Chief Executive Officer of PharmaVentures, he actively participates in many consultancy assignments. Dr Frank Grams, VP, Head of R&D Alliance Management & Transactions, Sanofi Frank joined Sanofi in September 2011 as VP, Head R&D Alliance Management & Contracting. In this function he is leading the early stage technology contracting activities and the R&D Alliance Management organization up to POC. Before coming to Sanofi he has been working for Roche as Executive Director, Roche Partnering Asia, and as such has been instrumental in setting up the Roche Pharma Partnering office in Shanghai starting in The office has been strengthening Roche s presence in the region from China to Australia. Prior to taking up this post, Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic and lifecycle management activities related to drug delivery partnering. Frank was a Global Alliance Director from 2002, managing pivotal research alliances such as Chugai, Evotec, SGX, Syrrx and Biotie. He has been involved in more than 100 transactions including product and technology deals, in- and out-licensing opportunities and also an acquisition. He is also one of the initiators of the Greater China Life Sciences Business Plan Competition SEED ( Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, having previously worked in various research functions in Roche and at Boehringer Mannheim GmbH. Frank has a degree in chemistry from the University of Heidelberg and received his Ph.D. with summa cum laude from the Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at Martinsried, Germany).

11 Speakers Genghis Lloyd-Harris, Partner, Abingworth Management LLP Genghis joined Abingworth in 2004 from Credit Suisse First Boston (CSFB) where he was a Managing Director in the European Equity Research Group based in London. Genghis was responsible for coverage of the European biotechnology industry and was ranked first for Pan-European Biotechnology in the Institutional Investor surveys each year from 2001 to Before joining Equity Research at CSFB, he worked for CSFB s Health Care Group in the Investment Banking Division in New York. Genghis was previously a paediatrician in Melbourne, Australia. His current and past directorships have included HBI, Novexel, Solexa, Synosia Therapeutics and Syntaxin. Genghis holds a Medical Degree from the University of Liverpool in the UK, a PhD in Clinical Pharmacology from the University of Melbourne, Australia, and an MBA from Harvard Business School. He focuses on exits of Abingworth s venture investments via mergers and acquisitions and IPOs as well as venture investment in the UK and Continental Europe. Graeme Martin, President and CEO, Takeda Research Investment, Inc. Graeme Martin is President and CEO of Takeda Ventures, Inc (TVI), the corporate venture arm of Takeda Pharmaceutical Company, Ltd. Since joining Takeda in 2003, Dr Martin has overseen investment of $54mm into 19 early and mid-stage biotechnology companies, many of which have resulted in strategic relationships with Takeda R&D operations, and one of which Envoy Therapeutics, Inc. was acquired by Takeda in During more than 30 years R&D management in multinational Pharmaceutical and Biotech companies in Europe and the USA, Dr Martin has led teams that have delivered three novel drug candidates and an acute treatment for migraine, zolmitriptan, now marketed worldwide under the brand name Zomig. He is and is the author of more than 85 peer-reviewed publications and book chapters. He received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK. Hamza Suria, President and CEO, AnaptysBio, Inc. Mr. Suria joined AnaptysBio in December 2008 and has been CEO since Prior to AnaptysBio, Mr. Suria was at Maxygen, where he was responsible for partnering and alliance management of next-generation protein therapeutics with Roche, Sanofi-Aventis, Bayer, Astellas and others. Before Maxygen, Mr. Suria was responsible for business development at Diabetogen Biosciences and Viron Therapeutics. Suria holds a B.Sc. in biochemistry from Kalamazoo College, an M.S. in immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business. Hartmut Ruetten, Head Translational Medicine Diabetes R&TM, Sanofi Hartmut Ruetten graduated in Medicine at the University of Cologne in He worked in the Department of Internal Medicine/Cardiology at Clinic II of Medicine at the University of Cologne from From he worked as a post-doctoral Fellow at the William Harvey Research Institute (London) under the direction of Sir John Vane, with a grant from the Deutsche Forschungsgemeinschaft/Royal Society. In 1996, he joint Hoechst as a lab head in the cardiovascular pharmacology department and was appointed as group leader in pharmacology in Aventis, After the merger of Sanofi- Aventis in 2005, he was appointed as head of the Cardiovascular Department in Frankfurt. In 2010 he was appointed as head of the Translational Medicine group within the newly formed Diabetes Division of Sanofi-Aventis. The focus of his work is on diabetes, obesity and cardiovascular complications of diabetes. The primary task of his group composed of experts in biomarker, bioinformatics as well as clinical pharmacology is to translate basic research into proof of concept in patients. In addition, he is coordinator of the IMI (Innovative Medicine Initiative of the European Union) consortium: DIRECT (DIabetes REsearCh on patient stratification) comprised of 21 academic institutes and 4 pharmaceutical companies. The overarching aims of this consortium are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to the treatment of type 2 diabetes (T2D) with either existing or novel therapies.

12 Speakers Heinz Schwer, Senior Director, MorphoSys AG Dr. Schwer is Senior Director of MorphoSys and responsible for the company s corporate venture activities called Innovation Capital. He joined the company in 2010 after he has sold Sloning Biotechnology to MorphoSys. Heinz Schwer co-founded Sloning in 2000 and managed the company as Managing Director from 2005 until In the years before, he held the positions as Chief Operating Officer and Head of R&D. Heinz Schwer spent several years as postdoc at the Harvard Institute of Medicine and the Dana-Farber-Cancer Institute in Boston. In this time, he has received numerous awards, including a fellowship for his research in the field of leukemia disease and the biogenesis of blood platelets. He obtained his Ph.D. in clinical chemistry from the University of Regensburg and holds an MBA from Henley Management College in UK. He is also a founding member and Vice President of the International Association of Synthetic Biology. Dr Jaume Masana, Licensing & Strategic Partnering Director, Esteve Dr. Jaume Masana is Chemical Engineer (Institut Químic de Sarrià, Barcelona). He got a PhD in Organic Chemistry. His doctoral thesis consisted in the development of a unique asymmetric synthesis catalyzed by synthetic polypeptides, trying to mimic natural enzymatic processes. The new synthetic method produced in certain cases optical purities exceeding 90%, and results were published in several articles in the most prestigious European Chemistry journals. He also got a MBA and other relevant titles in Business Management. Dr. Masana has more than 25 years of experience in the pharmaceutical industry having had responsibilities in a variety of areas including: API production, research and development of new chemical entities, Business Development and Licensing. He has successfully completed numerous Co-development and Licensing deals (in and out) with all type of pharmaceutical companies including Big Pharmas and Biotechs from different geographic areas (USA, Canada, Europe, Japan, South Korea). He has also played a key role in the development of innovative Strategic Alliances, Public Private Partnerships and Joint Ventures. Dr. Jaume Masana lives in Barcelona, where a number of pharmaceutical companies, new biotechs, researchers, doctors and health professionals develop one of the most intense scientific activities in the Mediterranean and South of Europe areas. Jesús Martin-Garcia, General Partner, Eclosion2 Jesús started his career at the World Economic Foundation, and later at McKinsey & Co. focusing on Pharma and Food industries. In 1991 Jesús chose the entrepreneurial path, becoming the co-founder of LeShop, Switzerland s largest and most successful e-commerce company, and investing seed capital and supporting the creation of a number of other start-ups such as Silverwire or VTX. His entrepreneurial drive led to the launch of the Eclosion platform in 2004, to translate breakthrough science into life-altering drugs. This platform is a unique structure, with a public-private partnership that drives projects from the lab to clinical trials, as demonstrated by companies such as GeNeuro and GenKyoTex. These companies that were started as exploratory programs in the incubator are now testing first-in-class drugs in Phase II clinical trials. Jesús has a MS in Economics and a Master in Law from University of Geneva, and an MBA from Harvard Business School. He chairs the Board of Eclosion start-ups such as GeNeuro and ArisGen, and sits on the Boards of several Industry and Trade associations. John Clarkson, CEO, Atlas Genetics Ltd. John has a background in genetics and microbiology and has been in healthcare and diagnostics businesses for the past 15 years. He co-founded Molecular Sensing plc in 1999, where he was Technical Director. Following the development of their DNA analysis system, he joined the US-based diagnostics company Osmetech as Instrument Systems Director when they acquired Molecular Sensing plc in John is now Chief Executive of Atlas Genetics, which is developing molecular rapid tests for infectious diseases such as the sexually transmitted diseases Chlamydia and Gonorrhoea. Atlas Genetics was founded in 2005 as a joint spin-out from the University of Bath and Osmetech plc. The company raised 18.5m in 2011 in a series B financing round led by Novartis Venture Funds.

13 Speakers Jonathan Garen, Assistant Vice President Business Development, Forest Laboratories, Inc. Jonathan is an Assistant Vice President of Business Development at Forest Laboratories, Inc., where he has worked since His responsibilities include the identification, evaluation, and negotiation of transactions for new business opportunities in a wide range of therapeutic areas and stages of development, including licensing and acquisitions in the fields of neurology, inflammation, oncology and metabolic diseases. Prior to Forest, Jonathan was a Director in the Global Licensing department at Pharmacia Corporation. Jonathan was a founder and Vice President of TechEx, an online licensing exchange for early stage opportunities, and was a Licensing Associate at the technology licensing office of Yale University. Jonathan earned his Master of Environmental Sciences from Yale University and his Bachelor of Science in Physics from the Massachusetts Institute of Technology. Judith Hills, Vice President, Corporate Business Development, Ipsen Biopharm Limited Judith Hills PhD, Senior Vice President, Corporate Business Development (CBD) joined Ipsen Biopharm in January Based in Slough UK, Judith reports to the Executive Vice President of Corporate Strategy at Ipsen and brings her skills and experience to lead the team of BD professionals to align deal activity to the new company strategy. Judith has led her team to execute several early R&D deals as well being instrumental in the acquisition of Syntaxin. Judith joined Ipsen from GlaxoSmithKline where she headed up Alliance Management and, prior to that, was Vice President of Business Development for Emerging Markets R&D. Judith also worked for Bristol Myers Squibb from 2002 to 2009 and was instrumental in a number of deals and partnerships, in her global roles, as VP Europe Business Development and then as Vice President Global Search & Evaluation. Prior to joining BMS, Judith spent her other industrial career years at SmithKline Beecham and GlaxoSmithKline, in pure R&D research as programme leader, Drug Development roles and latterly from 1987, as Senior Director with therapeutic roles in Worldwide Business Development. Judith started her career in industry after completing her PhD at University College London and two postdoctoral research positions also at University of London Colleges, UK. Judith carried out basic science research in GI and CNS disease. As a well-known BD professional, Judith has a deep understanding of the basic science, disease landscape, therapeutic intervention strategies, and the current regulatory and competitor environment. Juhani Lahdenperä, CEO, Hermo Pharma Ltd Juhani has served as the Chief Executive Officer of Hermo Pharma Ltd. since February Mr. Lahdenperä holds a degree in biochemistry from the University of Oulu. Before joining Hermo Pharma Mr. Lahdenperä served as a Chief Executive Officer in Plex-Press Ltd., a gene expression analysis technology company, that he co-founded in Thus, he has 5+ years of CEO experience from VC backed organizations. Previously, he held managerial positions at the University of Helsinki and Wallac Inc. (Perkin Elmer, Inc.). Some of this work has been published in high-profile journals such as Nature. Katya Smirnyagina, Partner, Capricorn Venture Partners Katya joined Capricorn Venture Partners (Belgium) in 2012 as a Partner in the Health Tech Fund. Prior to this, she was for 10 years with Alta Partners (San Francisco, CA) where she focused on European healthcare investment opportunities. She has worked in business development and management consulting before starting in venture capital Katya obtained a Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and received her Bachelor of Science in Biochemistry with high honors from Moscow University in Russia. Katya completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. She has co-authored a number of scientific papers. Katya Smirnyagina is independent board member of Adocia SA (France).

14 Speakers Keith Blundy, CEO, Cancer Research Technology Keith joined CRT in 1998, became COO in 2004 and was appointed CEO in Since then he has overseen the expansion of the CRT Discovery Labs to 85 staff and subsequent initiation of risk sharing discovery alliances with AstraZeneca and Cephalon, the establishment of CRT Inc in Boston (USA) as a business development arm of CRT and the further globalisation of CRT s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia. After completing a PhD at the John Innes Institute and a post doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programmes before transitioning to healthcare through business development. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd and Chroma Therapeutics Ltd and currently is on the board of Cytosystems Ltd and Cancer Therapeutics Pty. Lorenza Castellón, Independent Consultant Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe and Australia. Prior to joining Equity Development in January 2005 she held similar roles at leading international investment organisations. Equity Development brings together investors and companies by means of writing and distributing detailed research. We provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate metrics. Over the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of experience. Please visit for more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international investment organisations. Magali Gibou, Senior Regulatory Affairs Manager, Transgene S.A. Magali is a Regulatory Affairs professional with more than 14 years experience in the Pharmaceutical Industry based in France, with her most recent position at Transgene S.A.. She is specialised in European & US Pharmaceutical/Biologics Regulatory Affairs from preclinical to clinical development stages. She has experience managing regulatory strategies until MA submissions, regulatory interactions with health authorities and regulatory operations for projects at global, national and European levels. Especially, she has hands on management of regulatory affairs for a Drug-CDx program in oncology, implying closed connections with both Drug and CDx regulatory authorities. Malcolm Weir, Co-Founder and Chief Executive Officer, Heptares Therapeutics Ltd Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as co-founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997 and is on the Chemistry and Chemical Biology Advisory Boards at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from

15 Speakers Manfred Horst, Director Business Development, Merck & Co./MSD Dr. Manfred Horst studied medicine in Munich, Montpellier and London and specialised in Allergic Diseases at the University Clinic in Montpellier, where he also completed his PhD. After earning his MBA at INSEAD, Fontainebleau, Manfred spent 7 years with Ciba-Geigy and Novartis, Basel, two years as General Manager of a startup in the health insurance business, and up until now 14 years with Merck & Co./MSD. Since 2004, Manfred has been in his current function as Director Licensing & External Research Europe, where he scouts for Licensing opportunities and manages alliances in a number of European countries. Mark Bleckmann, Director & Head of Finance, immatics biotechnologies GmbH Following degrees in business administration and philosophy, Mark Bleckmann started his career at IBM, where over the course of 9 years he held roles of escalating responsibilities in various finance and planning functions. In his last position at IBM he was Finance Manager of the Frankfurt office and one of Europe s largest outsourcing contracts at the time. He joined immatics in 2008 where he is responsible for managing all finance matters and as well as other administrative functions of the company. In 2010 immatics successfully closed a C financing round, raising 54m. Markus Hosang, General Partner, BioMedPartners AG Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in pharmaceutical research and in many product development and marketing areas, with special expertise in the areas of biotechnologies, strategic alliances, and theranostics/diagnostics. Before joining BioMedPartners in 2004, Dr. Hosang was a Venture Partner at MPM Capital, where he was co-responsible for their European deal flow, and served on the boards of several European portfolio companies. Previously, he was at Roche in Basel, where, for nearly 20 years, he held several senior management positions in the Pharma R&D organization, including Vice President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Chief Scientific Officer of Genetics and Integrated Medicine, and a member of the Roche Genetics Executive Committee. He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduate training at Stanford University Medical School in neurobiology and subsequently at the University of Washington in Seattle in vascular dieseases. Dr. Hosang served on the Board of Directors and the Board of Trustees of the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its Treasurer from He currently is a member of the boards of Okairos AG, Suppremol GmbH and Anergis SA (as interim Chairman of the Board). Earlier he was on the boards of Omrix, Kourion (until its merger with ViaCell), IDEA, Atugen, Avontec and Neuraxo. He has published more than 30 articles in peer reviewed journals, and is coinventor on several patents. Dr. Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting Dr. Martina Kaufmann is founder and managing director of Martina Kaufmann Strategic Consulting offering individual solutions for personalized medicine. She is a pharmacist with scientific track record in molecular biology and >14 years of hands on experience in personalized medicine from a technology / diagnostic as well as from a pharmaceutical perspective across the lifecycle. Dr. Kaufmann has a comprehensive, inter-divisional background with experience not only in drug development/translational medicine, molecular diagnostics, and molecular imaging, but also in marketing, sales, project management, and business development in biotech start-up as well as global pharmaceutical organizations. She established and implemented consolidated project specific biomarker / diagnostic strategies for various oncology development projects in exploratory and full development, as well as for market adoption and lifecycle management of marketed targeted therapies/companion diagnostics, e.g. Herceptin /HER2. She also has experience in molecular imaging agent development, enabled market entry of a microarray based protein profiling system in Europe and successfully launched a microarray based pharmacogenetic profiling system.

16 Speakers Nanna Lüneborg, Investment Director, Novo Seeds, Novo A/S Nanna joined the Novo Seeds investment team in March Prior to joining Novo A/S, she worked for Apposite Capital, a London-based healthcare venture fund, where she was responsible for diligence of new investment opportunities and involved in all aspects of investment activities, deal structuring and execution. She also gained experience in portfolio management through observer roles on three company boards, two of which were in drug development and a medical device company. Earlier in her career, she worked at Cancer Research UK as a research manager, and as a consultant on various biotech and healthcare venture projects during her MBA studies. She holds a 1st class BA from University of Oxford, a PhD in Neuroscience from University College London as a Wellcome Trust Scholar, and an MBA with distinction from University of Cambridge, where she was a Sainsbury Scholar. Nanna serves on the board of Affinicon, and as an observer on the Board of Directors of Avilex Pharma and Galecto Biotech. Oliver Schacht, CEO, Curetis AG Oliver is a well-known expert in the diagnostics industry with a distinguished career at Epigenomics AG. He served as CFO of Epigenomics AG (Berlin, Germany) and as CEO for Epigenomics, Inc. (Seattle, USA). He has an extensive track record in strategy development and implementation, fund-raising (including IPO), finance, M&A, and alliance negotiation. Oliver Schacht holds a diploma in European Business Administration from the European School of Business in Reutlingen and London, as well as a Master s and Ph.D. degree from the University of Cambridge (UK). During his tenure at Mercer Management Consulting, he worked on projects in M&A, growth strategies and reorganization in pharmaceutical, biotechnology, and other sectors. To Curetis, he brings a strong background in the molecular diagnostics industry ranging from technology development through discovery and clinical validation to the market launch of molecular tests. Peter E. Burckhardt, CEO, EVA the Basel life sciences start-up agency Peter plays an important role in supporting innovation in Northwestern Switzerland. His main focus is life sciences start-ups. Peter is CEO of EVA the Basel Life Sciences Start-up agency. This company was founded in 1996 with the aim to support life sciences start-ups with coaching, access to a high value network and providing seed money. In addition he is CEO of the BASEL INCUBATOR, which he helped to establish 2 years ago. The BASEL INCUBATOR is a joint venture of the University of Basel, the University of Applied Sciences of Northwestern Switzerland (FHNW) and the Canton of Basel-Stadt. To complement his activities, Peter is the president of the BioValley Business Angel Club, the only Business Angel s Club in Switzerland focusing entirely on life sciences / MedTech. Peter has a PhD in chemistry from the University of Basel and joined Ciba-Geigy / Novartis 1984 as a research chemist. Throughout his professional career he had managerial positions with worldwide responsibility in technical development, regulatory affairs, manufacturing, production and communication and was the CEO of the subsidiary of a sector of Novartis in Germany. He joined EVA in Peter Llewellyn-Davies, CFO, Medigene AG Peter Llewellyn-Davies was appointed as Chief Financial Officer and Member of the Executive Board of Medigene AG with effect from 1 October He has over 25 years of experience in senior positions in medium-sized companies in the commercial as well as the financial sector. Prior to joining the company, he was CFO of WILEX AG in Munich and was responsible for a broad range of functions including accounting, controlling, finance, legal, human resources and investor relations. He was a member of Wilex s Executive Management Board from 2006 until the end of August Over this time he was instrumental in the initial public offering, key strategic transactions and acquisitions as well as their integration, and a range of capital measures. Prior to this, he was Managing Director of Müller Dairy (UK) and Executive Finance Director at Süd- Chemie AG, where he oversaw the international expansion of the Munich-based company. Mr. Llewellyn-Davies read business management, banking, marketing and controlling in London (UK), St. Gallen (Switzerland) and Munich, and has a certificate in business studies from the University of London. SPEAKERS

17 Speakers WELCOME Dr Philippe Calais, CEO, Antisense Pharma GmbH Dr Philippe P. Calais is Chief Executive Officer of Antisense Pharma since March 1, He has over 25 years of biopharmaceutical and pharmaceutical industry experience in both North America and Europe. Prior to joining Antisense Pharma, he was the President and CEO of Univalor, the largest technology transfer organization located in Montreal, Canada. He has managed biopharmaceutical companies in Canada and served as a consultant to life science companies, focusing on corporate strategic positioning, company deployment and sales optimization strategies. His management expertise, combined with extensive experience with large pharma companies such as ICI Pharmaceuticals and Roche, covers the full scope of the drug chain from discovery to clinical development, commercialization as well as partnership and franchise strategic marketing for several therapeutic areas. He has a degree and doctorate in pharmacy from the U. F. Rabelais, Tours, France. SPEAKERS Pierre-Olivier Goineau, EVP & COO, ERYTECH Pharma SA Before co-founding the company, Pierre-Olivier was Senior Consultant in Strategy and Development at KPMG in Lyons, France, where he was in charge of the Health division. Pierre-Olivier is Vice-President of the Board of Directors of France Biotech, the French association for biotechnology. Pierre Olivier has a DEA (post-graduate degree) in Management Science and a Master s degree in Pharmaceutical Industry Management from the IAE (School of Business Management) in Lyons, France. Rainer Metzger, VP, Global Head Business Development Pharma, QIAGEN Rainer Metzger, PhD: A proficient, solution-driven executive with achievement record in global leadership, business development, and execution of successful organizational and product development programs for pharmaceutical and diagnostics companies. Currently VP, Global Head Business Development Pharma with QIAGEN responsible for the initiation and management of global partnerships for companion diagnostics programs and previously as VP, Global Head Pharma Partnerships from with LEICA BIOSYSTEMS, a DANAHER company. From 2002 to 2010 working at Roche in various functions as VP, Global Business Development Diagnostics, Head Oncology Molecular Diagnostics in Roche Diagnostics; Head Clinical Biomarker Program and Head Global Biomarker Operations in Roche Pharma. From working in entrepreneurial functions with several Biotech companies in Business Development, Marketing and CEO functions. Rainer Strohmenger, General Partner, Wellington Partners With over 20 investments in start-up companies, Dr. Rainer Strohmenger is one of Europe s most experienced venture capitalists in life sciences. Joining Wellington Partners ( in 1997, he became a Partner in December His more than sixteen years of investment activity have involved financing of some of the most successful European biotech, medtech, and diagnostics companies. In the late 1990s Dr. Strohmenger co-managed Wellington s investment in Swiss biotech player Actelion (SWX: ATLN; www. actelion.com), today a listed company with a market capitalization of more than six billion Euros. He also was responsible for the investments in Grandis (acquired by Novartis), NoemaLife (Borsa Italiana: NOE; Wavelight (acquired by Alcon), 20/10 Perfect Vision (now Technolas Perfect Vision; acquired by Bausch & Lomb), immatics ( as well as mtm laboratories (acquired by Roche; and represents Wellington on the boards of the portfolio companies Implanet ( invendo medical ( Oxford Immunotec ( Quanta Fluid Solutions ( and Genticel ( Prior to joining Wellington Partners, Dr. Strohmenger was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany. Dr. Strohmenger holds a Ph.D. in medicine as well as a M.Sc. in economics, both from Ludwig-Maximilians-University in Munich, Germany, and was trained at the Entrepreneurship Center of the MIT, Boston, USA. Dr. Rainer Strohmenger is 46 years old, married and has three daughters.

18 Speakers Rudi Pauwels, Executive Chairman & CEO, Biocartis Dr. Rudi Pauwels (Belgium) is a pharmacist who started as a researcher at the Rega Institute for Medical Research in Leuven, Belgium, an academic research center that is internationally known for its pioneering work in the field of antiviral chemotherapy. For more than two decades Rudi mainly focused on (i) the search and development of anti-hiv drugs, a number of which have been approved and introduced on the market and (ii) the development of diagnostic tools to allow personalized HIV treatment. His research as well as his entrepreneurial career is driven by medical needs and the passion to advance and significantly impact medicine. He (co)-founded several biotech companies: 1994: Tibotec Antiviral Drug R&D: mainly HIV, later extended to HCV Co-Founder & CEO, CSO, VP Research 1995: Virco HIV pharmacogenomics Co-Founder & Chairman, CSO 1999: Galapagos Genomics Tibotec-Crucell joint-venture, functional genomics: drug target discovery Chairman, Board member 2003: OncoMethylome Sciences/MDxHealth Originating from Virco projects and research at John s Hopkins: early biomarkers of cancer 2007: Biocartis Diagnostics Executive Chairman (CEO until end 2011) Rudi is (co-)author of more than 150 publications in peer reviewed journals. He received several awards for his scientific and entrepreneurial initiatives; amongst others an honorary doctorate at the University of Ghent, Belgium. Sarah Holland, Global Head of Strategic Partnering, F. Hoffmann-La Roche Ltd. Sarah Holland is the Global head, Strategic Partnering for Roche Partnering based in Basel, Switzerland. Her team s projects include broad strategic landscapes of M&A and late stage opportunities, transactional support for all pharma M&A transactions, initiatives to generate income through divestments, spin-outs and strategic partnerships, and development and delivery of creative deal structures to address key business needs. In 2010 the team acquired world-wide rights to danoprevir from Intermune and supported the acquisition of Marcadia Biotech. Since joining Roche in 2005, Sarah has held various responsibilities in business development, such as Global Head of CNS Partnering, and has led projects in a range of disease areas, including the Plexxikon deal on b-raf inhibitors. Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast cancer during US and EU launch. She held various commercial and strategic roles over her ten years there, including Global Strategic Planning Manager for early compounds, Pricing Strategist and Health Economist. Before AstraZeneca, she held local and international sales and marketing roles in diagnostics, biotech and pharmaceutical companies. Sarah gained her MBA from Manchester Business School, where she was a Visiting Fellow until 2004, and her D.Phil and first degree at Oxford University. Seong Chen, Project Leader, Strategic Initiatives, Global Business Development, F. Hoffmann-La Roche Ltd. Seong Chen started at Roche Diagnostics Chief Technology Office (Berkeley, CA) in 2002 as Technology Analyst. After working 5 years in Pricing and Finance, Seong relocated to Rotkreuz, Switzerland in 2007 to lead the Strategic Pricing & Commercial Affairs group at Roche Professional Diagnostics. In this role, Seong has developed pricing strategies and supported many new product launches. Since April 2011, Seong has beenappointed the Project Leader in Roche Diagnsotics, Basel to lead a division initiative in Pricing & Reimbursement. Seong studied Electrical Engineering at University of Melbourne, Australia and received a MBA from University of Berkeley, California. Prior to Roche, Seong worked at Schlumberger and Boston Consulting Group.

19 Speakers Stefan Weber, CEO, NEWRON PHARMACEUTICALS SPA Stefan Weber was appointed Chief Executive Officer of Newron effective June 1, He had been Chief Financial Officer of the Company since April Stefan holds a master s degree in business management from FernUniversität Hagen (Diplom-Kaufmann). He has more than 25 years of industry experience in finance and has been serving as Chief Financial Officer of public and private biotechnology companies since From 1987 to 1999, he was with Lohmann Group, a worldwide producer of pharmaceutical, medical, technical and consumer products. His final position was Head of Finance of the group. After joining Girindus, a fine chemistry process development and scale-up provider in 1999, he was appointed Chief Financial Officer in From 2001 to 2005, he was the Chief Financial Officer of Biofrontera, a company active in drug discovery and development. Stefan Weber has been responsible for executing numerous ransactions of substantial deal value, including M&A, debt, equity and mezzanine financing as well as national and European grants. He has executed IPOs to the stock exchanges in Frankfurt and Zurich. He furthermore has been involved in a number of disinvestments and strategic restructurings. Stefan Weber is German. Dr. Stefanos Theoharis, Chief Business Officer, apceth GmbH & Co. KG Dr. Stefanos Theoharis joined apceth in 2013 from Antisense Pharma, where he was Head of Business Development. Prior to that, he was Business Development Director of Emerging Technologies for F. Hoffmann-La Roche (Roche), based in Basel. Before joining Roche, he was an M&A Analyst, focusing on life sciences, with Lazard, in London. He has a PhD in cell and gene therapy from Imperial College London, where he subsequently worked as a Research Fellow in several academic departments. Stéphane Boissel, Executive Vice-President & Chief Financial Officer, Transgene Stéphane Boissel is Executive VP & Chief Financial Officer in charge of finance, business deals structuration and negotiation, administration (personnel, legal, IT and purchasing departments) and Investor Relations. Between 2002 and 2010, he was VP & Chief Financial Officer of Innate Pharma where he piloted the company s IPO and was responsible for negotiating business development agreements. Between 1995 and 2002, Stéphane worked as an investment banker in the Lazard Group and spent four years in Singapore and Hong Kong. He began his career in 1990 as a financial auditor within PWC. Stéphane has an MBA from the University of Chicago (Booth GSB) and has degrees in finance from the universities of Lyon and Paris Dauphine. He is a SFAF member and helds a DSCG. Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners Stephanie Léouzon is Principal and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in She also serves on the Board of Directors of Immunovaccine Inc. Previously she worked in Health Care Investment Banking in the US and Europe from , most recently at Credit Suisse as a Managing Director and Senior Advisor. She has advised life sciences clients on more than 20 strategic transactions, valued at over $65billion, and been involved in over 45financing transactions to provide over $10 billion to health care clients. Stephanie earned an M.B.A. degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a B.A. degree, cum laude, from Mount Holyoke College in 1985.

20 Speakers Thomas Jung, MD, Chief Medical Officer, Delenex Therapeutics AG Dr. Jung is an experienced Translational Medicine Specialist. He is Chief Medical Officer at Delenex, Zurich, Switzerland. Prior to that he was Head of Translational Medicine EU at Novartis, Basel, Switzerland, where he was responsible for all proof of concept studies in many major disease area s including autoimmunity, gastro-enterology, respiratory diseases, neuroscience and muscular -skeletal diseases. As Global Head Development of the Immunology and Infectious Diseases Franchise Dr. Jung was leading large multi-disciplinary teams involved in 11 major drug development programs from proof of concept studies to marketing authorization. At Novartis Dr. Jung conducted many successful proof of concept studies, both with low molecular compounds and biologicals. He was the driving force behind the successful registration of ILARIS ( Canakinumab ) for Cryopyrin Associated Periodic Syndromes and for expansion of its clinical utility in other diseases such as gout, Still s disease and type 2 diabetes. As a physician -scientist Dr Jung conducted immunological research at the Novartis Research Institute in Vienna, Austria, the DNAX Research Institute in PaloAlto, USA, the National Jewish Medical and Research Center in Denver, USA and the University of Marburg, Germany, from which he obtained his MD degree. Dr. Jung is a board certified dermatologist and he also holds an Associate Professor s position at the University of Gottingen, Germany. Tom Kronbach, CEO, BioCrea Tom Kronbach is CEO of BioCrea, which he established as a Management buy-out of assets from Biotie Therapies Corp. in A new Management Team and new scientific and business ideas were combined with a productive CNS-discovery group. The first success was the acquisition of BioCrea s Cognition Program by Boehringer Ingelheim in Since then new projects for Epilepsy, Autism, Depression and Huntington s disease were established. Tom has initiated and fostered partnerships with Boehringer Ingelheim, Wyeth/Pfizer and GlaxoSmithKline. Previously, Tom was the CSO of Biotie Therapies Corp. and CSO and co-founder of elbion AG. Tom holds a Ph.D. in Chemistry from the University of Tubingen, Germany. He was a Post Doctoral Fellow with Urs A. Meyer in Pharmacology at the University of Basle, Switzerland and was Research Associate in Molecular and Experimental Medicine with Eric F. Johnson in at The Scripps Clinic and Research Foundation in La Jolla, CA. Tom then joined Goedecke-Parke Davis in Freiburg, Germany and then Asta Medica -AWD, a Degussa company in Radebeul, Germany, where he had increasing responsibilities up to being Head of R&D. Dr Thomas Taapken, CEO, Epigenomics AG Dr. Thomas Taapken is CEO of Epigenomics AG since September He joined Epigenomics on April 1, 2011 as Chief Financial Officer. from Biotie Therapies (Finland), where he held the position of CFO and was a member of the Executive Management Team. He was appointed to this position in 2008, following a business combination between Biotie Therapies and elbion NV, where Thomas had been CFO since His extensive international experience in the life sciences industry includes previous positions as investment partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Franciscobased US venture capital firm Burrill & Company from He also worked several years at Sanofi-Aventis in the U.S.A. and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, he has been involved in numerous transactions spanning acquisitions, mergers, divestitures, as well as private and public offerings. Tim Knoterus, Business Development, AM-Pharma Tim joined the AM-Pharma team in June 2012 and is responsible for Business Development. Prior to joining AM-Pharma, Tim worked as Senior Associate at Aescap Venture, a venture capital company investing in European life science companies, where he has been involved in the investment in and support of several portfolio companies. Tim has a MSc in Science and Innovation Management and a MSc in Drug Innovation, both from Utrecht University (NL).

21 Speakers Vincent Charlon, CEO, Anergis Vincent Charlon joined Anergis in January 2009 as Chief Executive Officer (CEO). Dr Charlon brings over 20 years of global clinical development and management experience. From 1990 to 1998, at Hoffmann La Roche Basel as Clinical Research Scientist and then at Hoffmann La Roche Inc. Nutley,USA, as Director of Clinical Research, Dr Charlon held clinical development responsibilities for several international projects. He was the first author of an approved global new drug application for an antiantihypertensive and anti-anginal new chemical entity and was involved in numerous meetings with the US FDA and European regulatory authorities. From 1998 to 2006, Vincent Charlon was CEO of Hesperion Ltd., the contract research organization (CRO) who designed and conducted all initial clinical trials for Actelion s [SWX, ATLN] products. In this capacity, Vincent Charlon designed the first clinical trials of Tracleer in pulmonary hypertension, today Actelion s biggest product with sales well over CHF 1 billion/year. Vincent Charlon developed Hesperion as a profitable CRO from 3 to 200 employees located in eight country offices, serving over a hundred clients. Two third of Hesperion clients were small biotech companies from North America and Europe. During that time, Dr Charlon also realized two company acquisitions and integrations into Hesperion, as well as the sale of Hesperion to Cerep SA. In , Vincent Charlon was CEO of the drug repositioning start-up company LS Pharma International SA before joining Anergis. Vladimir Cmiljanovic, Chief Executive Officer, PIQUR Therapeutics AG Vladimir has hands-on experience in the range of chemistry disciplines (organic, medicinal, analytical & biochemistry) essential to the discovery of PI3K-Akt-mTOR pathway products. Vladimir built up the team of well-known and recognized experts from the field and is leader of the team creating PIQUR s industry leading next generation PI3K agents. For his scientific contribution in PI3K-AKT-mTOR research field he was awarded in 2009 with the Camille and Henry Dreyfus Award of the University of Basel and in 2011 with the Novartis and University of Basel Excellence Scholarship for Life Sciences. In 2010 Vladimir was the winner of the Swiss Venture Kick for the development of the PIQUR business idea. Wilder Fulford, Principal, Torreya Partners Dr. Wilder Fulford is the founding partner of Torreya Partners Europe, the London branch of Torreya Partners, an international advisory firm assisting Life Science companies with M&A, licensing, alliances, financings and other transactions. Dr. Fulford has had a long career advising healthcare companies of all kinds around the globe. After completing his PhD in molecular biology at the Rockefeller University in 1986, he worked for a few years as a venture capitalist, before embarking on a career as an M&A advisor. He has run healthcare M&A or coverage groups in New York and London at Salomon Brothers, Merrill Lynch, Bank of America and (most recently) Deutsche Bank. He has participated in close to 100 financing and M&A transactions with an aggregate value in excess of $100 billion. Torreya Partners has a full team in London, and about a dozen mandates in execution, and has closed five transactions so far in 2013 in biotechnology, specialty pharma, vaccines, medical devices, and OTC. Globally, Torreya Partners has completed over 100 Life Sciences assignments in the 6 years since inception. Willem van Weperen, CEO, to-bbb technologies BV Willem obtained a MSc degree in biomedical sciences from Utrecht University, and an Executive MBA degree from NIMBAS/ Bradford University. He began his professional career in clinical research at Glaxo and joined Genzyme in 1994 with responsibility for post-registration clinical trials for orphan diseases in Europe. Willem subsequently worked in several sales and marketing positions at Genzyme. Towards the end of 2003 he assumed global responsibility for marketing in the orphan disease business unit in Genzyme s worldwide headquarters in Cambridge, MA. In 2006 he transitioned to become General Manager of Genzyme Netherlands. Willem joined to-bbb as CEO in During his tenure at to-bbb Willem raised ±$10M of private equity and ±$5M in grants. This enabled growth of the organization from 10 to over 20 people, development of several CNS product candidates and initiation of clinical studies for to-bbb s products 2B3-101 and 2B3-201.

22 CONTACT Kevin FitzGerald PhD MBA, CEO John Vane Science Centre Charterhouse Square London EC1M 6BQ UK Activiomics Ltd Privately owned, main investor: IP Group. Activiomics has developed a suite of advanced, label-free mass spectrometry technologies that enables it to identify and quantify, directly from clinical samples, proteins and phosphoproteins that correlate with the progression of disease and/or with the administration of drugs. The company is applying these technologies to the establishment of a pipeline of biomarker assets comprising the identified proteins and phosphoproteins along with their companion diagnostic antibody reagents kevin.fitzgerald@activiomics.com The company also partners with the pharmaceutical and biotechnology industry to provide drug profiling and drug mode of action information. To date, the company has secured 8 collaborations including those with Genentech, UCB Celltech, GSK and Kyowa Hakko Kirin Dr Kevin FitzGerald, CEO Dr Neil Torbett, COO

23 CONTACT Dr Bernard Coulie, CEO and CMO Technologiepark Zwijnaarde Belgium ActoGeniX NV Within a year of its inception, ActoGeniX raised 23 million (approximately US$35 million), 20 million of which was obtained through a Series A equity round, one of the largest among European biotech start-ups. In July 2007, ActoGeniX announced the approval of a 3 million (approximately US$4.4 million) grant from the Institute for Promotion of Innovation by Science and Technology in Flanders (IWT), to support its innovative therapeutic drug development activities during a two-year period. In the first quarter of 2009, the Company announced that it had raised an additional 15.5 million (approximately US$20 million) from its strong syndicate of life sciences investors, including new investor Biovest (Belgium) as well as the existing investors. In the second quarter of 2009, ActoGeniX was awarded a 0.9 million grant (US$1.3 million) by IWT, to support the clinical development of AG013, a novel ActoBiotic for the treatment of oral mucositis in cancer patients. In April 2013, ActoGeniX raised 10.7 million through a Series B equity round. ActoGeniX s syndicate of experienced life sciences investors includes companies such as Gimv, Biotech Fund Flanders, Baekeland Fund, BioVest (Belgium), LSP, Aescap Venture (The Netherlands), Ventech (France) and Saffelberg Investments Bernard.coulie@actogenix.com ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics, a novel class of orally available biopharmaceuticals for the treatment of GI, mucosal and immunological diseases Dr Bernard Coulie, Chief Executive Officer and Chief Medical Officer Dr Anjan Aralihalli, Chief Business Development Officer Dr Lothar Steidler, Sr. Director Technology Development Dr Pieter Rottiers, Director Preclinical Operations Dr Sam Corveleyn, Director CMC and Qualified Person Mr Emil Pot, Director Legal & IP Ms Magda Van Hijfte, Director Finance and Administration

24 CONTACT Frauke Hein, PhD Chief Business Officer Neuendorfstraße 15a Hennigsdorf bei Berlin Germany Adrenomed AG Privately funded by founders and angel investors. Actively fundraising for clinical program to clinical POC (Q3/ ). Adrenomed AG is a lean virtual biotech company, established by a experienced scientific and senior entrepreneur team of Prof. Tamas Bartfai, Scripps Institute, La Jolla and Dr. Bernd Wegener and Dr. Andreas Bergmann, the latter both beeing former executives of BRAHMS AG. Our mission is to develop innovative first-in-class drugs that reduce the mortality in life-threatening acute care conditions like sepsis and kidney diseases, with high unmet need and limited treatment options. Adrenomed is pursuing a unique and highly innovative approach by attacking the underlying disease biology in a novel and safe way and with a proposed disease-modifying mechanism. The target Adrenomedullin (ADM) is a strong vasodilatory peptide and an important regulator of vascular tone and blood pressure. However, excessive ADM may be involved in severe hypotension associated with organ failure and elevated ADM levels in patients have been shown to be the strongest risk factor for death. Our lead compound Adrecizumab is a highly specific and potent humanized monoclonal antibody designed to target ADM with the potential for use in acute hypotensive indications. Adrecizumab represents a new drug class of first-in-class modulating (non-neutralizing) antibodies which are designed to control harmful excess target activity whilst maintaining beneficial target function. This groundbreaking and patent protected mode-of-action has shown excellent preclinical efficacy in acute kidney injury and sepsis and offers a favorable safety profile. We expect to start First-in-Man clinical testing end of (0) (0) fhein@adrenomed.com 2009 Dr Bernd Wegener, CEO Dr Andreas Bergmann, CSO Dr Frauke Hein, CBO

25 CONTACTS Stefan Fischer, CFO Dr Guido Koopmans, Head of R&D Max-Planck-Str. 15a Erkrath Germany Algiax Pharmaceuticals GmbH The company has already raised 4,3 million Euro s in Series A financing from a consortium of private and statebacked investors to get the approval for the lead compound for entering the clinical phase. To start phase I/II Algiax is looking for a further 6-8 Mio. 2 of funds. The new financing will be under participation of the current investors. Series B financing is due to start in March Algiax Pharmaceuticals GmbH is an independent biotechnology company that was established in April It is dedicated to the discovery and development of innovative products in the field of nervous system disease or dysfunction with a strong focus on neuropathic pain. The company s lead compound AP-325 is in late preclinical development and is ready to enter clinical trials by mid The primary indication is neuropathic pain, the secondary indication is spinal cord injury for which Algiax has an orphan drug designation. Algiax has created a strong and effective protection of intellectual property. Next to that Algiax has identified NCE s that are currently in the early development phase but have a huge potential for an even stronger pipeline in the near future. With our lead compound ready to progress into clinical development and several NCE s in discovery/preclinical development, Algiax is well positioned to take advantage of the market opportunity not only in the field of neuropathic pain but also in other unmet nervous system disorders. +49 (0) (0) info@algiax.com 2011 Dr Jürgen Schumacher, Chief Executive Officer Stefan Fischer, Chief Financial Officer Dr Guido Koopmans, Head of R&D Dr Birgit Hasse, Associate Head of R&D

26 Alpine Institute for Drug Discovery MISSION The goal of the Alpine Institute for Drug Discovery (AIDD) is to perform translational drug discovery in open innovation collaborations with academic researchers and to sell resulting drug candidates, during lead optimization, to the pharmaceutical industry. Specifically, AIDD will identify early-stage academic research with therapeutic potential and, via collaboration, leverage our proven discovery and development competencies to generate high value drug candidates that can be out-licensed to pharmaceutcial partners or spun out of AIDD into special purpose vehicles (e.g. startup companies) during lead optimization. With regard to therapeutic focus, AIDD will initially seek to prioritise targets with potential as immunotherapeutics for oncology, auto-immune, and inflammation disease; although AIDD will be opportunistic with regard to therapeutic focus.

27 CONTACT Dr Volker Rindler, Director Business Development Robert-Roessle-Str Berlin Germany ALRISE Biosystems GmbH Current Investors: IBB Beteiligungsgesellschaft Creathor Venture Dr. Giuseppe Vita Total investments from previous financing rounds: EUR 5 million Revenue in 2012: EUR 1.4 million (break-even) Additional capital requirement: Up to EUR 10 million Current investors are committed to participate Intended use of additional capital: Financing of own clinical development programs ALRISE develops controlled release depot formulations for protein, peptide and small molecule drugs. The cornerstone of ALRISE s business is its patented drug delivery technology for the encapsulation of hydrophilic or hydrophobic drug substances in biodegradable polymeric nano or micro particles. ALRISE not only offers a unique technology, but also provides a platform from which products can be developed to meet the ever increasing needs of pharma, biotech, and generics companies. ALRISE s mission is to make its innovative encapsulation technology available to a broader user spectrum and ultimately to create benefit for patients worldwide. Among ALRISE s strengths are: Unique technology: ALRISE is positioned in the sweet spot of drug delivery. Its ImSus platform technology is an elegant solution to optimizing delivery of proteins, peptides, and small molecules, covering the future trends in pharma and biotech drug development. Among some of the key aspects are the technology s simplicity its one pot process which shortens product development time-lines and lowers manufacturing costs relative to competing technologies, its flexibility allowing it to be applied to diverse drug classes, release durations and administration routes, and its categorical elimination of carcinogenic solvents and harmful. Solution to product lifecycle management: With the pharmaceutical industry facing increasingly difficult pipeline challenges many are turning to lifecycle management of blockbuster products to extend the revenue from these successful franchises. Large pharma companies are developing controlled release formulations of key products, examples of which are already marketed Risperdal Consta (Johnson & Johnson), Bydureon (Eli Lilly), or Lupron Depot (Abbott). This translates into significant opportunities for drug delivery companies such as ALRISE which offer the key to product and pipeline extensions. +49 (0) Dr Volker Rindle +49 (0) r +49 (0) info@alrise.de rindler@alrise.de Dr Celal Albayrak, CEO Dr Volker Rindler, Business Development Dr Heiko Seemann, Formulation Technology

28 CONTACTS Erik van den Berg CEO Tim Knotnerus BD Rumpsterweg AK Bunnik The Netherlands AM-Pharma Raised EUR 29.2 million in AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. AM-Pharma is based in Bunnik, The Netherlands. Based on the strong results of the Phase II trials with bovine Alkaline Phosphatase in Acute Kidney Injury and a Phase II trial in Ulcerative Colitis. AM-Pharma developed an innovative recombinant form of human Alkaline Phosphatase. This recombinant Alkaline Phosphatase will be used in future trials and for commercialization. AM-Pharma raised 29.2M in Q4 2011, enabling AM-Pharma the development through phase II. In September 2013, AM-Pharma started recruiting healthy volunteers in a phase I study for its lead program in Acute Kidney Injury Office@am-pharma.com e.vandenberg@am-pharma.com t.knotnerus@am-pharma.com 2002

29 CONTACTS Hamza Suria, President & CEO Cindy Stewart, Executive Admin Pacific Center Court Suite 200 San Diego, CA AnaptysBio, Inc Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. AnaptysBio s proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene, Gilead, DARPA and DTRA. Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S. For more information, visit hsuria@anaptysbio.com cstewart@anaptysbio.com 2005 Hamza Suria, President & CEO David King, Chief Scientific Officer Chuck Covington, Head of Finance

30 CONTACTS Vincent Charlon PhD, CEO Zoltan Czigler MBA, Finance Director BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland Anergis SA CHF 22M funding received from venture capital and private investors Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel allergy vaccines targeting the most frequent allergies. Anergis vaccines are based on its proprietary Continuous Overlapping Peptides ( COP ) technology. Allergies are the most prevalent and the fastest growing chronic conditions in the industrialized world, with over 500 million people affected. Anergis lead-product AllerT, a vaccine to treat birch pollen allergy, is in Phase II clinical development. AllerR, its vaccine candidate for the treatment of patients with allergy to ragweed pollen has received positive feedback from the U.S. FDA for the final preclinical and early clinical program and AllerDM, Anergis vaccine candidate for patients with house dust mite allergy, is progressing through preclinical development. Anergis has raised over CHF 22 million from Renaissance PME-Vinci Capital, Sunstone Capital, BioMedInvest and other investors including Esperante Ventures and Defi Gestion. Anergis COPs reproduce the full-length amino acid sequence of the allergen in separate long peptides. COPs do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be safely administered at high doses to induce tolerance to the allergen after few injections only. Studies of COPs in vitro, in animals and in humans have confirmed the safety (no immediate allergic reaction) and immunogenicity (production of specific IgG4 antibodies and cytokines against the original allergen) of ANERGIS COPs. In a Phase I/IIA trial with AllerT, a trend for symptom improvement was observed during the season and long term follow-ups of the same patients demonstrated that antibodies against the birch pollen major allergen bet v 1 were still significantly elevated in comparison with placebo-treated patients, two and four seasons after the very short one-time preseasonal treatment (5 SC injections in 2 months) with AllerT. A large double-blind, placebo-controlled, randomized, multicentre European trial is underway with AllerT to demonstrate the efficacy of AllerT using recommended regulatory endpoints of combined symptom and medication scores in real-life conditions, i.e. during the natural birch pollen season. Results of this trial are expected in Q At this time, Anergis intends to partner AllerT for Phase III and/or to finance it through a round B with current and new investors info@anergis.ch 2001 Vincent Charlon, PhD, CEO Christophe Reymond, PhD, CSO François Spertini, MD, Allergy Expert, Founder Gilles Della Corte, MD, Clinical Development Eva Castagnetti, PhD, Product Development Gerard Farmer, PhD, Regulatory Affairs Jean Paul Rohmer, PhD, Business Development Zoltan Czigler, MBA, Finance

31 CONTACTS Dr Philippe Calais CEO Dr Andrea Kottke Head Medical Affairs & Communication Leopoldstrasse Munich Germany Antisense Pharma GmbH Privately held company. Equity lead investor is MIG fund. Others are S-Refit and Bayern Kapital. Antisense Pharma has an unmatched commitment to developing TGF-ß inhibitors that stimulate the human immune system to effectively fight cancer. We are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. We are focused on the various isoforms of TGF-ß, a key pathway in cancer that plays a significant role in a tumor s ability to suppress the immune system and avoid detection Dr Philippe Calais, Chief Executive Officer a.kottke@antisense-pharma.com 1998

32 CONTACT Stefanos Theoharis, Chief Business Officer Location Munich / Grosshadern Max-Lebsche-Platz 30 D Munich Germany Location Munich / Ottobrunn Haidgraben 5 D Ottobrunn Germany +49 (0) apceth GmbH & Co. KG Privately held company. Apceth is a clinical stage biopharmaceutical company in the Munich area focused on the development of native and genetically modified cell therapeutics ( Advanced Therapy Medicinal Products, ATMPs). We combine the principles of adult stem cell biology with pioneering technologies and the highest standards for GMP manufacturing and quality management, according to European and international guidelines. We offer contract GMP manufacturing and related services to customers around the world, using our expertise, high standards and state-of-the-art GMP/BSL2 facilities of more than 600 m2 of cleanroom area (class ISO8, ISO7, ISO5), quality control units and R&D laboratories. Our manufacturing license covers native and genetically modified cell therapeutics, according to 13 and 20b of the German Medicines Act (AMG). We are the first company worldwide to receive approval for a phase I/II clinical trial with genetically modified mesenchymal stem cells for the treatment of advanced gastrointestinal cancer (start 10/2013). In parallel, our first clinical phase I/II trial for the treatment of critical limb ischemia with our somatic cell therapeutic is currently ongoing. +49 (0) contact@apceth.com s.theoharis@apceth.com 11/2007 Christine Günther, MD, CEO Professor Ralf Huss, MD, PHD, CSO Helmut Jeggle, CFO

33 CONTACT Dirk Beher, PhD, Chief Scientific Officer PSE-B EPFL 1015 Lausanne Switzerland Asceneuron SA Asceneuron SA has raised to date EUR 5M seed funding from Merck Serono Ventures. The Company Asceneuron was formed in Octo-ber 2012 through the spin-off of Merck Serono s Alzheimer s dis-ease drug discovery portfolio and research group. The company comprises a highly experienced management team combining both scientific and drug discovery expertise with a business and fundraising background. Asceneuron develops effective therapeutics for Alzheimer s disease and related neurodegenerative diseases such as tauopathies. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neuro degenerative diseases. Due to increasing life expectancy, Alzheimer s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression. The Asceneuron team of eight people is located at the Science Park of the Ecole Polytechnique Fédérale Lausanne (PSE). This team has already worked for more than four years on the key molecules since the inception of our drug discovery programs. At the PSE we operate in a state-of-the-art facility in proximity to the Brain Mind Institute. Technology & Product Information Asceneuron s unbiased approach is to develop both symptomatic and disease modifying treatments for Alzheimer s disease based on known pathophysiology. We are targeting the decline in cognition, the accumulation of tau protein into neurofibrillary tangles and the generation of toxic amyloid-ß 42 peptides. Our molecules are predicted to provide an early proof of concept for larger Alzheimer s disease trials. For the treatment of tauopathies we are targeting the pathology of toxic tau in Progressive Supranuclear Palsy and Frontotemporal dementia with the aim to achieve orphan drug status. Asceneuron will initially focus on moving three preclinical programs with significant commercial potential for Alzheimer s disease from lead optimization into clinical testing. All of Asceneuron s small molecule lead compounds have CNS drug properties with demonstrated target engagement in the brain upon a single oral dose in preclinical models. Our M1 muscarinic acetylcholine receptor positive allosteric modulator (M1 machr PAM) is aimed at improving cognitive function by stimulating cholinergic neurotransmission. Cholinergic signaling is a key pathway that has already been successfully exploited for drug development. Therefore we anticipate a greater probability of success for new and better tolerated drugs that target this clinically validated pathway. The O-GlcNAcase inhibitor pre-vents the removal of O-linked ß-N-acetylglucosamine carbohydrate moieties from the micro-tubule-associated tau protein thereby reducing the formation of neurofibrillary tangles. Neuro-fibrillary tangles are a key hallmark of the pathology and major contributor to the neurodegeneration in Alzheimer s disease and tauopathies. We will actively explore the orphan drug path for our O-GlcNAcase inhibitor program with the aim to get an early proof of concept in a major tauopathy. Finally, our g-secretase modula-tor reduces the production of toxic amyloid-ß 42 peptides without inhibiting the y-secretase enzyme. This can be predicted to lead to an efficient amyloid-ß lowering drug whilst avoiding the mechanism-based toxicities observed with g-secretase inhibitors. Our Business Model Asceneuron s approach is the enhancement of the value of our assets by progressing our high quality lead compounds to clinical testing for Alzheimer s disease and tauopathies. Once this stage has been reached we will explore a variety of options such as partnering or outlicensing. Our unbiased approach allows us to capitalize on the renewed interest for improved symptomatic treatments and in addition to take advantage of the increased industry focus on tau targeting approaches. continued...

34 CONTACT Dirk Beher, PhD, Chief Scientific Officer PSE-B EPFL 1015 Lausanne Switzerland Asceneuron SA We view both our M1 machr PAM and the O-GlcNAcase inhibitor programs as highly competitive with first in class potential. Our current funding allows optimal resourcing of the M1 machr PAM cognition program to reach clinical testing latest in the first quarter of Asceneuron seeks additional funding to ensure support of the highly innovative O-GlcNAcase inhibitor and the secretase modulator program and to secure the progression of the M1 machr PAM in clinical development. We are initially seeking additional funding of EUR 10M to move the O-GlcNAcase inhibitor into clinical testing and to progress the M1 PAM program through Phase 1 clinical studies. Dirk Beher (PhD), Chief Scientific Officer Dirk Beher is a founder of Asceneuron SA and joined the company as Chief Scientific Officer. He led the spin-off proposal for Merck Serono s Alzheimer s disease portfolio and successfully raised EUR 5M seed funding which materialized in the creation of Asceneuron SA in October Dirk has more than 21 years of experience in the field of Alzheimer s disease and spent over 15 years in pharmaceutical drug discovery. Previously, Dirk was the director of the Neurobiology Unit at Merck Serono in Geneva, Switzerland. He was responsible for the strategic build-up of Alzheimer s disease as a new indication and implemented the projects which represent Asceneuron s pipeline. Prior to Merck Serono Dirk worked in the Neuroscience Department at Amgen Inc. in Thousand Oaks, California where he oversaw a diverse CNS portfolio as management team member. Dirk started in pharmaceutical drug discovery by joining Merck Sharp & Dohme in Harlow, United Kingdom in During that time he made key contributions to the secretase inhibitor MK 0752 and was finally responsible for all secretase programs. Dirk holds a Ph.D. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor of seven patents and currently authors 47 peer-reviewed publications and reviews. Frank M. Armstrong (M.D.), Executive Chairman of the Board & Business Advisor Frank Armstrong is an experienced, medically qualified, Pharmaceutical Executive who has worked to Board level in the UK, US, Switzerland and Germany. He currently works as an Independent Advisor, Consultant and Board Member to Life Science Companies through his own consulting company. Most recently he led Medical Science and Innovation (MSI) in R&D at Merck Serono and previously led Worldwide Development at Bayer and the Worldwide Medical Organisation at Zeneca. He has extensive experience of all aspects of Medical Development and Product Development in large and small company environments where he has led successful product approvals for the US and EU across a range of therapeutic areas. He has been the CEO of 5 Biotechnology companies (public and private) and was CEO of Fulcrum Pharma, a profitable, Professional Services Company, sold to Private Equity Investors. In 2007 he led the sale of 454 Life Sciences for CuraGen to Roche for $154 million. Frank has experience as a Non-Executive Director in the UK and USA with private and a NASDAQ listed companies and as Chairman of a Charitable Institution. He is currently Chairman of Xceleron, a Board Member at Summit PLC and Actino Pharma and a Member of the SAB at Healthcare Royalty Partners. Christoph Wiessner (PhD), Head of Discovery Christoph Wiessner is a founder of Asceneuron and Head of Discovery of the company. Previously he was a director in the Therapeutic Area Neurodegenerative Diseases at Merck Serono ( ), and headed the CNS Target and Lead Discovery Unit at Novartis in Basel ( ). There he also led the drug discovery team for CAD106, a vaccine for Alzheimer s Disease currently in Phase II, and contributed to several CNS projects that entered into clinical testing. He obtained his PhD in the department of Nobel laureate Hartmut Michel at the MPI for Biophysics, Frankfurt, Germany. He then joined the department of Konstantin-Alexander Hossmann at the MPI for Neurological Research, Cologne, Germany, and concluded this work with a habilitation in Experimental Neurology at the Medical Faculty of the University of Cologne. He authored 59 peerreviewed publications and book chapters.

35 CONTACT Carina Schmidt, CEO Sankt Eriksgatan 117, 4th floor Stockholm Sweden Athera Biotechnologies AB Current shareholders, including Karolinska Development AB (publ), Baltic Sea Foundation and KCIF Coinvestment Fund AB, have invested approximately e18 m in the company. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. Athera has an exclusive option agreement with Boehringer Ingelheim. Karolinska Development AB owns 65% of Athera Biotechnologies AB. PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine ( PC ), and will be indicated for secondary prevention to improve outcome after revascularisation in PAD patients. Low endogenous levels of antibodies to phosphorylcholine ( anti-pc ) have been linked to a higher incidence of secondary events in CVD. This program is in IND-enabling studies and the start of Phase I studies is expected in To enhance clinical success by properly selecting the target population, Athera has developed a proprietary companion diagnostic CVDefine kit to identify patients with low anti-pc levels in need of receiving PC-mAb therapy. The kit is CE-approved. Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory bio-therapeutics and companion diagnostics for the prevention and treatment of cardiovascular disease ( CVD ). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institute. The company currently has a proprietary pre-ind program, PC-mAb, supported by an approved proprietary companion diagnostic kit c.schmidt@athera.se 2002 Athera is managed by a team of senior professionals from the pharmaceutical and diagnostics industries in a semi-virtual organization. The core team is led by CEO, Carina Schmidt. Ms. Schmidt has nearly 30 years industrial experience, mainly in business development and management, international marketing and product management within the biotech area. During 15 years she has worked with Pharmacia Biotech/Amersham Biosciences (now GE HealthCare). Later she founded Grasp Bioscience and co-founded BioBusiness Partners Scandinavia, where positions included management consultant, interim CEO and business advisor to several biotech start-ups.

36 CONTACTS Dr John Clarkson Chief Executive Karen Yates Finance Director Derby Court, Epsom Square, Trowbridge BA14 0XG, UK Atlas Genetics Revenues for sexually transmitted infection tests: 80m 70m 60m 50m 40m 30m 20m 10m 0 Assumptions First commercial revenues in UK in 2015 and launch in Rest of Europe and US in 2016 (FDA) Launch moderately complex, obtain CLIA waiver 2018 (applicable to US only) Direct sales in UK, via distributor for US and Rest of Europe Market penetration by % in UK, 4% in Europe and US john.clarkson@atlasgenetics.com karen.yates@atlasgenetics.com 2005 Atlas Genetics Ltd is a UK-based clinical diagnostics company that has developed a rapid solution to point-ofcare (POC) molecular diagnostics. The io system is fast (30 mins), multiplex, fully integrated & easy to use, low cost and accurate. A menu of infectious disease tests, focusing on sexually transmitted infections and hospital acquired infections has been developed. Other application areas include pharmacogenomics and industrial microbiology. The company was established in 2005, and completed a 18.5 series B financing in 2011 led by Novartis Venture Funds, and including Johnson & Johnson Development Corp, Life Science Partners (LSP), BB Biotech and Consort Medical plc. Dr John Clarkson, Chief Executive Karen Yates, Finance Director Nick Higgins, Business Development Director Ben Arlett, Technical Director Daniel Adlerstein, R&D Director James Castelow, QA & Regulatory Affairs Director

37 CONTACT Rudi Pauwels CEO Biocartis SA EPFL Quartier de l Innovation, Bat G 1015 Lausanne Switzerland Biocartis NV Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis ambition is to establish a new gold standard in diagnostic testing. Biocartis innovative research and diagnostic systems are characterized by multiplex detection and simplified workflows which require less hands-on time and minimize sample requirements (especially for tumor biopsies). Additionally, Biocartis develops assays which have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis is well suited to address the growing need for individualized diagnosis and treatment of cancer patients. Biocartis is a rapidly growing company; to date Biocartis staff includes over 170 people. Biocartis NV Generaal De Wittelaan 11 B Mechelen Belgium Switzerland Belgium info@biocartis.com 2007 Executive team Rudi Pauwels, CEO Hilde Windels, CFO Erwin Sablon, Head of Assay Development Geert Maertens, CSO Inge Basteleurs, General Counsel Chris Heymans, Director Quality & Regulatory Chris Gabriëls, Director of Operations Ulrik Cordes, CCO Nader Donzel, CTO

38 CONTACT Tom Kronbach, CEO BioCrea GmbH Meissner Strasse Radebeul Germany BioCrea GmbH Private Company, funded by project income BioCrea develops new small molecule drugs for debilitating CNS diseases such as Epilepsy, Autism, Dpression or Huntington s disease. The company s team has an exceptional track record in the development of CNS drug candidates and has partnered extensively with major pharmaceutical companies such as Boehringer-Ingelheim, Pfizer, Wyeth and GlaxoSmithKline. biocrea is based in Radebeul, Germany Tom Kronbach, Tom Kronbach, Chief Executive Officer Dr Martin Gunthorpe, Chief Scientific Officer Prof Simon Ward, Executive Vice President Chemistry & Development infobiocrea@biocrea.com tom.kronbach@biocrea.com 2010

39 CONTACTS Kinneret Savitsky CEO Philip Serlin Chief Financial and Operating Officer Tali Yudelman-Schori Executive Management Assistant 19 Hartom Street Jerusalem Israel BioLineRx Ltd. $23 million cash as of June, 30, employees Annual cash burn is approximately $12 million BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization. BioLineRx s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late For more information on BioLineRx, please visit or download the investor relations mobile device app, which allows users access to the Company s SEC documents, press releases, and events. BioLineRx s IR app is available on the itunes App Store as well as the Google Play Store taliy@biolinerx.com phils@biolinerx.com 2003 Kinneret Savitsky, PhD, Chief Executive Officer Philip Serlin, CPA, MBA, Chief Financial and Operating Officer Moshe Phillip, MD, VP Medical Affairs Leah Klapper, PhD, VP Research and Development David Malek, MBA, VP Business Development

40 CONTACT Mark Lundstrom CEO BioScale 4 Maguire Road Lexington, MA USA BioScale Venture backed through 4 rounds. Commercial growth stage. Instruments deployed across 10 countries thus far, generating consumable stream. BioScale is currently finalizing a financing round that is anticipated to be its last private financing. Most of round complete, seeking last money into round. BioScale is rapidly emerging as a new gold standard for detection and measurement of specific proteins, bacteria, and rare cells. BioScale has invented the proprietary Acoustic Membrane MicroParticle (AMMP ) assay. AMMP is embodied within BioScale s ViBE product line. With BioScale s ViBE, researchers and clinicians are able to achieve more sensitive, reproducible, and sample-robust measurements in the most complex of biological samples. BioScale s initial focus is in oncology and is rapidly expanding into other markets. BioScale s AMMP technology is a unique non-optical (acoustic) homogeneous assay that easily enables new assays. In the hands of top key opinion leaders in academia, government, and industry, BioScale outperforms the currently recognized gold standards on all important performance dimensions. BioScale s business model is a razor/blade business where a growing installed base of instruments generates a healthy consumable stream per machine. BioScale sells open system capability as well as kits. BioScale is first selling research use applications where no regulatory approval is required. BioScale is also already in CLIA labs and CROs and is soon to launch clinical applications and partnerships. mark@bioscale.com 2002 Mark Lundstrom, CEO and Founder Dr Brett Masters, CTO Dr Michael Miller, VP of Product Development/Operations Dr Martin Latterich, CSO

41 CONTACTS Vladas Algirdas Bumelis Mokslininku str. 4 LT Vilnius, Lithuania Vladas Algirdas Bumelis Biotechpharma Biotechpharma owns a brand new laboratory complex and state-of-the-art production facility (constructed and validated in 2012). Biotechpharma is led by an experienced team of professionals with advanced scientific degrees (e.g. M.Sc. or Ph.D.) in their area of expertise and extensive industry experience. The team ensures timely and quality execution of every project. Areas of expertise: cell line development and cell banking; high productivity biosynthesis process development; efficient protein refolding and downstream processes development; technology transfer; process characterization and validation; cgmp compliant analytical services ; stability studies; stable protein formulation development; drug substance and drug product cgmp manufacturing; project management. info@biotechpharma.lt Vladas.bumelis@northway.lt 2004 Utilizing one-stop-shop concept the company provides full range of services including, but not limited to: production strain development; upstream and downstream process development and optimization; manufacturing of drug substance and drug product (Proof-of-concept, preclinical, Phase I-III and commercial). Vladas Algirdas Bumelis, Chairman of the Board and CEO Vladas has served as Chairman of the Board for biotech companies Biofa and Biotechna until 1999, as well as General Manager of Sicor Biotech (later member of TEVAPharmaceuticals) until In 2004 Prof. Vladas Algirdas Bumelis received the science Award of Lithuania in recognition of his achievements in science and technology in developing and producing recombinant proteins. Tomas Bubinas, site COO Tomas is responsible for all operational activities who has over ten years of pharmaceutical and biotechnology experience. After starting his career in public accounting with Coopers&Lybrand, he joined Sicor Biotech, and after Sicor s acquisition by TEVA Pharmaceuticals expanded his role into the Pharmaceutical group. Most recently he served as Sr. Director at TEVA Biopharmaceuticals USA, where, he was responsible for CMO relationship management. Edita Mištinien, Ph.D., R&D Director Edita has more than 15 years experience in the biopharmaceutical industry and has worked with genetically modified microorganisms and recombinant proteins since She serves as Biotechpharma s R&D Director and is the leader behind our scientific activities working together with our clients scientists to solve challenges in biopharmaceutical development and manufacturing of their biopharmaceutical products. Edita worked in Sicor Inc. biotech, subsequently worked as R&D Manager at TEVA Pharmaceuticals. For the last three years she has been working as R&D Director at 3P Biopharmaceuticals, one of the leading European CMOs.

42 CONTACT Dr Josef Scheiber Managing Director Garmischer Str. 4/V Munich Germany BioVariance GmbH BioVariance offers innovative data analysis services for Drug Discovery and Development. We bring data from experiments in context with data available and come thereby up with testable hypotheses. One key focus is interpreting NGS data for pharmacogenomics. These efforts are supported by in-house software developers. In this area we currently work with 3 Big Pharma companies. In parallel we are currently developing (supported by a grant from the Bavarian Government) a knowledge platform for personalized medicine for children. The objective is to bring this knowledge into clinical usage, but the same can also be applied in Pharma Dr Josef Scheiber, Managing Director info@biovariance.com 2012

43 CONTACT Oliver Boucher Parc d activités économiques du WEX, Rue de la Plaine, 11, B-6900 Marche-en-Famenne Bioxodes Bioxodes was created to exploit the results of work conducted by Prof. Edmond Godfroid at the Ectoparasite Molecular Biology Unit, part of the University of Brussels (ULB), in collaboration with prestigious academic research units at the Université Catholique de Louvain, the Facultés Universitaires Notre Dame de la Paix Namur, the Université de Liège, all in Belgium and the Université de Neuchâtel, Switzerland. The company s goal is to develop a range of pharmaceutical and other bioscience products derived from natural sources. The company s initial focus is Ir-CPI, a unique antithrombotic peptide offering a remarkable and unprecedented balance between antithrombotic benefit and hemorrhagic side effect. oliver.boucher@bioxodes.com

44 CONTACT Wolfgang Kintzel, CEO CAP-CMV GmbH Gottfried-Hagen-Str. 62 D Köln CAP-CMV GmbH Privately funded GmbH Initial funding from existing CEVEC investors of e700 k to set-up the company and complete process optimization Investors: Peppermint, Creathor, NRW.Bank, KfW, SKBB and private investors Sought: Necessary milestone-driven funding (until exit in 2018): e9.7 M. CAP-CMV GmbH is a spin-out of CEVEC Pharmaceuticals GmbH and focuses exclusively on the development of a novel vaccine protecting against human Cytomegalovirus (HCMV) infection. The approach of CAP-CMV is the use of non-infectious HCMV dense bodies (DB), which is currently one of the most convincing technology approaches to develop an efficient CMV vaccine. In combination with CEVEC s unique human cell line expression system (CAP ), the novel vaccine can be produced at industrial scale using a serum free, suspension culture environment. The novel dense body based vaccine (product code CAP-CMV-001) as well as the CAP cell line are protected by a strong patent portfolio info@capcmv.de kintzel@cap-cmv.de 2013 Wolfgang Kintzel, CEO Dr Gudrun Schiedner, CSO

45 CONTACTS Larry C. Heaton II President & CEO Tom Kelley Sr. VP & CEO Cardiox Corporation 4100 Horizons Drive Suite 100 Columbus, Ohio Cardiox Corporation With recently obtained international regulatory clearance, informed by market research studies and armed with Leads generated via preclearance Medical Meeting interactions, Cardiox is launching internationally in 4Q13, and in the United States upon regulatory clearance. Worldwide sales are forecast to exceed $1 million in 2013, rising to $7 million in 2014, reaching cash flow breakeven and profitability in late Cardiox Corporation is a diagnostic medical device start-up now embarking on commercialization of its first product, for cardiac shunt detection, with its next product, for liver function testing, in clinical and regulatory development. Cardiox proprietary technology provides non-invasive detection and measurement of small amounts of an indicator dye injected via IV. Cardiox first product, the FDS Flow Detection System, enables a highly sensitive, low-cost procedure for shunt detection that a nurse or physician can perform in an office setting in about 15 minutes. Call points include Interventional and Echo-cardiologists as well as Stroke Neurologists. In the aggregate, the market opportunity for cardiac shunt detection exceeds $1.2 billion worldwide. Next on the product line-up is the LFA Liver Function Assessment system that enables real-time measurement of global liver function by determining the ICG clearance rate. The LFA system provides historically important clinical metrics, with hundreds of clinical studies documenting their use, simply and consistently at the bedside! Call points include Liver surgeons, Hepatologists and Gastroenterologists. In the aggregate, the market opportunity for liver testing exceeds 1.1 million patients and $1.5 billion worldwide Larry C. Heaton II ext cell Tom Kelley ex larryheaton@cardiox.com tomkelley@cardiox.com 2008 Larry Heaton, President & Chief Executive Officer Bob Lash, MD, Sr. VP & Chief R&D and Engineering Officer Phil Eggers, Founder & Chief Technology Officer Tom Kelley, Sr. VP, Finance & Chief Financial Officer Tony Blair, Sr. VP, Operations Karen Matis, VP, Quality & Regulatory

46 CONTACTS Daniela Couto, CEO David Braga Malta, President and EVP Biocant Park, Núcleo 04, Lote 4A Cantanhede, Portugal Cell2B Cell2B is a Portuguese-based biotech developer of cell therapies for immune and inflammatory diseases. It was incorporated in 2011 with technology developed by its founders and licensed from the Massachusetts Institute of Technology (MIT) in Boston and Instituto Superior Técnico (IST) in Lisbon. An early clinical study of the technology showed that it was safe and, in three patients already suffering from Graft-versus-Host-Disease, resulted in either complete or partial response. Key manufacturing and regulatory milestones have been achieved. Orphan designation has been granted in Europe. Daniela Couto, PhD, Chief Executive Officer at Cell2B. Dr Couto co-founded Cell2B and served as CEO since then. Her expertise is in business and clinical development for emergent therapies, namely cell therapies. She received her Ph.D. in Bioengineering from Technical University of Lisbon, with work done at MIT in Boston. David Braga Malta, PhD, co-founder, President of the Board and Executive Vice President at Cell2B. He has made significant scientific achievements in developing animal-free stem cell products, being the co-inventor of patent PCT/US2013/ filed by MIT and licensed by Cell2B. Rui Horta e Costa, Chief Financial Office at Cell2B. With 30-years of experience in the financial and industrial sectors, he was the Managing Director of UBS Investment Banking Division in London and the head of the Utilities Team for EMEA. Before UBS, he was the CFO of EDP and executive board member at Nutrinvest, both leading companies in energy and food sectors, respectively. Pedro Andrade, PhD, co-founder and Operations Director at Cell2B. He is the co-inventor of patent PCT/PT2013/ in the field of dynamic cell processing filed by IST and licensed by Cell2B. Francisco Santos, PhD, co-founder and Scientific Director at Cell2B. He has expertise over 8-years in processing mesenchymal stem cells and in translating it into clinical practice. Since 2007 he has been working with the Portuguese Institute of Oncology in Lisbon to apply these cells to patients with severe grades of GvHD.

47 CONTACT Oliver Schacht, PhD, CEO Curetis AG Max-Eyth Strasse Holzgerlingen Germany Curetis AG Raised EUR 49.1 million in equity capital Investors include: aeris Capital; HBM Partners; BioMed Invest; LSP; Forbion; Roche Venture Fund; CD-Venture; KfW Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. To date, Curetis has raised total funds of over e49.1 million (~ USD 65 million). The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical, Sanofi Pasteur and Cempra Inc. as well as several international distribution agreements. Oliver Schacht, PhD, CEO Andreas Boos, CTO Johannes Bacher, COO Dr Gerd Lüdke, Director Bio-Assay Dev Dr med Anne Thews, Medical Director Dr Klaus Brinkmann, Director Sales Dr Helmut Hilbert, Head of BizDev Heiko Schorr, Director Finance oliver.schacht@curetis.com contact@curetis.com 2007

48 CONTACTS Peter Ohnemus, President & CEO Othmarstrasse Zurich Switzerland dacadoo Private company dacadoo has developed an easy-to-use, wireless, secure and fun way to manage your personal health from a lifestyle, wellness and chronic disease perspective called the dacadoo Health Platform. The platform calculates your personal dacadoo Health Score, a number from 1 (poor) to 1,000 (excellent). The dacadoo Health Score is the key indicator of your current health status. By integrating gaming and social networking principles, dacadoo motivates you to be active in an easy way by automatically tracking and comparing your personal health, fitness, lifestyle and sport. The dacadoo Health Score has been developed by dacadoo in collaboration with a professor and former long-term scientist at MIT in Boston. The score is based on several tens of millions of person-years of clinical data and incorporates many of the well-known cardio and cerebrovascular risk studies in addition to dacadoo s quality of life questionnaires. The company is currently engaging with strategic partners from the telecommunications, healthcare, fitness, media and health insurance industries to serve both corporate and private clients. dacadoo has offices in Zurich, Switzerland and in San Francisco, USA. peter.ohnemus@dacadoo.com 2010 Peter Ohnemus, President & CEO Manuel Heuer, COO

49 CONTACT Thomas Jung, MD Chief Medical Officer Delenex Therapeutics AG Wagistrasse 27 CH-8952 Schlieren Switzerland +41 (0) (0) Delenex Therapeutics AG Series A round financing completed in May 2011; 30.2 MCHF Delenex Therapeutics AG is a clinical stage Swiss biotechnology company established in September It is focussing on the development of single chain therapeutic antibodies discovered by its proprietary, validated PENTRA platform. Delenex is developing those antibodies for topical and local use in man. While organs such as lung, gastrointestinal tract, bladder and skin are amenable for topical/local therapy, Delenex has focussed on delivering the novel concept of topical antibodies in fistulising Crohn s Disease and Psoriasis. In Crohn s Disease, draining abdominal and perianal fistulas were treated with Delenex frontrunner anti-tnf-α (DLX105) formulated in a gel. This randomized, placebo-controlled proof of concept study is currently running in Switzerland. In psoriasis, repeat injections of DLX105 into the dermis of psoriasis plaques mediated a clinical response showing that local inhibition of TNF-α is sufficient for a clinical effect. A new proof of concept study in psoriasis using topical DLX105 formulated in a gel has started and will deliver proof of concept results in the middle of Delenex has assembled an internationally recognized team with lots of years of experience gained in both the pharma and biotech world. It operates out of laboratories and offices in Schlieren/Zürich. For more details please review the company website thomas.jung@delenex.com 2009 Thomas Hecht, MD, Executive Chairman Jakob Schlapbach, CFO Thomas Jung, MD, CMO Titus Kretzschmar, PhD, CSO

50 CONTACT Stavros Therianos Diagnoplex SA, CEO Chemin de la Vuillette 4 CH-1000 Lausanne 25 Switzerland Diagnoplex SA CHF 15 million in series A We are a dedicated and multi-disciplinary team united in bringing true innovation to personalized cancer care. Using our unique molecular workflow and state-of-the-art biostatistical tools, we develop blood-based cancer diagnostic tests. Our initial focus is on systematic screening for colorectal cancer. This is an area of increasingly urgent and unmet medical need as a result of an ageing population, and one that represents an estimated market opportunity of $3.5 billion. Diagnoplex lead product, Colox, is a convenient and non-invasive blood test developed for the systematic screening of colorectal cancer (Colorectal cancer). The gene signature underlying Colox detects early and advanced disease stages with outstanding results and reliability. Lothar Wieczorek, Ph.D., Executive Chairman Lothar Wieczorek has been at the forefront of the development of medical devices and products in the US and European Pharmaceutical and Diagnostics industries throughout his 30-year career, where he has held senior positions in R&D, Business Development, Strategic Planning and Medical Affairs. Stavros Therianos, Ph.D. CEO Stavros Therianos is one of the principal founders of Diagnoplex and has been with the company since Stavros is a consummate entrepreneur who brings his talent and passion to Diagnoplex science and business activities. Prior to the founding of Diagnoplex, he was an assistant professor at the University of Rochester Medical Center, USA. stherianos@diagnoplex.com 2005

51 CONTACTS Jim Weissman, CBO Douglas Fambrough, CEO Dicerna Pharmaceuticals, Inc 480 Arsenal St Building 1, Suite 120 Watertown, MA Dicerna Pharmaceuticals, Inc Dicerna is privately held Has raised $110 Million in capital since founding Most recently closed a $60 million financing in July 2013 Dicerna Pharmaceuticals is creating RNA interference (RNAi) therapeutics for a range of diseases, including rare diseases involving genetically-defined targets in the liver, and cancer indications with undruggable driver oncogenes. Dicerna uses it Dicer Substrate (DsiRNA) to silence these disease target genes, and delivers the DsiRNAs using Dicerna EnCore drug delivery technology. Dicerna s most advanced program, DCR-M1711, targets the MYC oncogene, and should begin human trials in early Douglas Fambrough, CEO Jim Weissman, CBO Bob Brown, CSO Paul Nadler, Acting CMO jweissman@dicerna.com dfambrough@dicerna.com 2007

52 CONTACT Ahmed Abdelaziz CEO Lichtenbergstraße Garching bei München Germany Office: (+49) Mob: (+49) (+49) Ahmed.abdelaziz@eadmet.com 2010 eadmet GmbH The company was founded in 2010 and received GO-Bio phase II funding that supports the company until Q4 / In 2011, eadmet received additional funding from High-Tech Gründerfonds and Bayern Kapital that brought the total funding of dilutive and non-dilutive capital to e1.45 million. eadmet focuses on the creation of customised computational models for the prediction of important ADME/ Tox properties of small drug-like molecules and peptides. The Company s modular approach combines proprietary and selected external algorithms in order to improve decision-making for clients and partners in the pharmaceutical and biotechnology industry and to add value by saving time and costs in drug design and discovery. In order to create a customised prediction model, eadmet incorporates the client s own experimental data and subsequently integrates the resulting model into the client s existing IT environment. eadmet s prediction models are developed using the Company s proprietary web-based OCHEM database of over 750,000 chemical structures linked to known physical and ADME/Tox characteristics. The Company s advanced integrative approach, including self-learning capabilities, delivers tailor-made models to predict values that are directly comparable to experimental results. eadmet s product offer enables new types of data-sharing syndicates to further accelerate drug discovery and save time and costs. Based on a 3-fold business model, eadmet promotes a free software version for academia, and licenses its software suite to industry partners in the Pharma, Biotech and chemical industry. Additionally to offering proprietary web-based informatics systems that integrate customers internal systems and data with software from other vendors, eadmet supports in a third step its customers with on-site training and implementation, web-based training and data migration services. Ahmed Abdelaziz, CEO Joachim Vogt, CBO

53 CONTACTS Christer Rosén Chairman and CEO Cheryl Varco, Head of Finance Wolleraustrasse 41B CH-8807 Freienbach EffRx Pharmaceuticals SA Private company planning IPO 2014 Specialty Pharmaceutical company. EffRx business approach is to make existing good pharmaceuticals better, thereby Creating New and Improved Therapeutic Entities serving our investors, partners, patients and payers Targeting improvements to leading medications, focused on convenience, compliance and tolerability, thus creating best in class products Provide improved quality of life to the patient by making medications easier to take Create lifecycle management opportunities for the pharmaceutical industry First product launched in USA Christer Rosén, Chairman & CEO Lorenzo Bosisio, CCO Dr. Timo Schmidt, CSO Cheryl Varco, Head of Finance

54 CONTACTS Pierre Belichard CEO Lydie Lancry PA 94 avenue Ledru Rollin PARIS Enterome Premoney valuation:3.8 Me A round (M ):7.5e Date: March 2012 Postmoney FD:12.3 Me Investors: Seventure LundbeckFonden Shire LLC Omnes Capital Danone Markets: Metabolic diseases Inflammatory bowel diseases belichard@enterome.com 2011 Enterome is a Paris-based company with the most advanced technologies in the emerging field of the human gut Microbiome. Enterome develops a pipeline of metagenomic markers based on profiling of the human gut microbiome. These biomarkers will be used to monitor disease evolution, stratify patients population or enable new treatments with the goal to improve management of microbiota-related diseases, e.g., metabolic, gastrointestinal, and autoimmune. These chronic disorders depend on genetic susceptibility (polymorphisms of the human genome), but are also triggered by environmental factors where dysbiosis of the intestinal bacterial ecosystem (gut microbiota) is a major contributor. Pierre Belichard, CEO Marie-Laure Bouttier, COO James Clark, CTO Rodolphe Clerval, CBO Pierre Rimbaud, CMO

55 CONTACT Antje Zeise Manager IR PR Epigenomics AG Kleine Präsidentenstr Berlin Germany contact@epigenomics.com 1998 Epigenomics AG Epigenomics is publicly listed at the Frankfurt Stock Exchange, Prime Standard: (ECX, ISIN DE000A1K0516) and has established a Level 1 ADR program in the U.S.A. (OTC: EPGNY). For financial information please refer to the Investor Relations section of the Company s website. Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics lead product, Epi procolon, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is under regulatory review by the FDA for the U.S.A. The Company s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A. Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the U.S. and Europe. The team is headed by Dr. Thomas Taapken (formerly Biotie Therapies, Deutsche Venture, Burrill & Company) and Dr. Uwe Staub (formerly Abbott Diagnostics, Digene and Qiagen). Dr. Thomas Taapken, CEO/CFO Dr. Uwe Staub, COO

56 CONTACTS Gil Beyen Chairman and CEO Pierre-Olivier Goineau EVP and COO 60, Avenue Rockefeller Bâtiment Adénine LYON France ERYTECH Pharma SA : ~1 million Seed : 17 million Series A 2013: 28 million IPO ERYTECH Pharma SA (NYSE Euronext Paris: ERYP) is a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs. The company s lead product GRASPA, asparaginase encapsulated in red blood cells, is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. In the United States, ERYTECH is launching a Phase Ib clinical trial in ALL investors@erytech.com 2004 ERYTECH has concluded distribution partnership agreements for Europe with the Recordati -Orphan Europe group, and with TEVA for Israël. The company has its own GMP approved and operational manufacturing site in Lyon (France) and a US location for cgmp clinical batches production at the American Red Cross in Philadelphia (USA). Gil Beyen, Chairman and CEO Pierre-Olivier Goineau, EVP and COO Yann Godfrin, EVP and CSO

57 CONTACTS Dr Jaume Masana Mr Marc Álvarez Mare de Déu de Montserrat 221, Barcelona, Spain Esteve Million TOTAL NET SALES : 792 INTERNATIONAL SALES :421 (53%) Esteve is a European pharmaceutical group, headquartered in Barcelona (Spain) and with operations, affiliates, commercial partners and production sites in three continents. The group is structured in three main activities: innovative pharmaceuticals, API production (with facilities in Mexico, Spain and China) and generics (with commercial affiliates in a number of countries in the EU, Turkey and the USA). Core activity is centred on the discovery, development, production and commercialization of first in class and/or best in class innovative pharmaceuticals. Esteve s R&D pipeline is composed of proprietary small molecules to treat different types of pain. Sigma 1 receptor antagonist is a first in class, orally available, proprietary drug, in Phase II clinical trials to treat neuropathic pain. In addition Esteve is developing a proprietary first in class, patent protected, co-crystal of two very well established API, for acute and chronic pain. A proof-of-concept Phase II clinical trial has been successfully completed very recently. In addition Esteve is involved in two Public Private Partnerships for the development of biotech projects (HIVACAT project for the development of a therapeutic and/or prophylactic HIV vaccine and a gene therapy project to treat Sanfilippo A syndrome) Esteve has been extremely successful in the in-licensing and commercialisation of first and best-in-class drugs, especially for the Spanish market. Such in-licensing deals and Strategic Alliances have been forged in the last decades with Big Pharma, innovative Japanese companies and selected Biotechs. Unparalleled record of commercial success (especially under co-marketing framework) is based on a very rigorous and serious scientific approach and on a differentiated and innovative commercial structure covering commercial, medical and market access aspects. Mr. Albert Esteve, CEO Mr. Jordi Esteve, BDL Director

58 CONTACT Risto Lammintausta CEO Itäinen Pitkäkatu 4B FI Turku Finland Forendo Pharma Ltd First financing round up to 10M (in two tranches) closed in June Forendo Pharma is a drug discovery and development company focusing on two programs acquired recently from Hormos Medical Fispemifene has demonstrated in phase II studies efficacy to normalize own testosterone in men with secondary hypogonadism. It maintains testicular function with once daily oral dosing and offers significant advantages over testosterone replacement. Forendo will develope fispemifene with partners. 17HSD1 inhibitor is in preclinical development targeted for treatment of endometriosis. This first-to-man compound has demonstrated unique profile in primates with elimination of endometriosis lesions while maintaining normal hormonal cycle. Forendo is looking additional investor of up to 4M to join the first investment round and to secure financing through the clinical POC of the novel endometriosis product and successful partnering of the programs Forendo team consists of the key experts of Hormos headed by Risto Lammintausta (MD,PhD) as CEO and board member. Other board members are today Stephan Christgau (chair) from Novo Seeds, Jyrki Mattila (MD) and Hans Postlind from KD Ab.

59 CONTACT Hans T Schambye, MD PhD CEO Dorte Dannemann Executive Assistant Ole Maaloes Vej 3 DK-2200 Copenhagen Denmark Galecto Biotech Galecto Biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company s products target galectins, a group of proteins that play important roles in many disorders. Galecto Biotech s high potency galectin inhibitors may open new treatment possibilities for many patients. The company is led by top-level scientists and biotech executives. Galecto Biotech is located in Medicon Valley in close proximity to the founders research groups. Hans Schambye, MD PhD, CEO Anders Pedersen, COO Prof Tariq Sethi, B.Sc., M.A., Ph.D., FRCP, CSO Prof Ulf Nilsson, PhD, Head, Med Chem Prof Hakon Leffler, MD PhD, Head, Immunology & Biology hs@galecto.com dd@galecto.com 2011

60 CONTACT Allen Baharaff CEO 8, Shaul Ha melech Blvd. Tel Aviv Israel Galmed Pharmaceuticals Ltd Current Round: up to $15M investment (soft close at $3M). Galmed Pharmaceuticals develops an innovative, proprietary family of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs), composed of naturally occurring compounds, the for treatment of Metabolic and Liver Diseases. These orally administrated compounds have the potential to treat NASH and improve other manifestations of the Metabolic Syndrome such as insulin resistance. Our lead candidate, Aramchol, is a first in class, potential disease-modifying treatment for NASH. Aramchol is the only safe compound that has been clinically shown, in a randomized, double blinded clinical trial, to reduce significantly liver fat content as well as improve metabolic parameters associated with fatty liver disease. Aramchol is a new chemical entity (NCE), which is a partial selective and safe inhibitor of SCD1 (one of the key enzymes in lipid metabolism). Aramchol also upregulates the ABCA1 Transporter (the universal cholesterol export pump) stimulating the Reverse Cholesterol Transport from cells. Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases, associated with insulin resistance, diabetes & obesity. NAFLD is diagnosed when infiltration of fat is increased in liver cells. It can be manifested as Steatosis, excess fat in the liver; as Steatohepatitis in which in addition to fat inflammation and liver cell injury occur; and the most advanced stage Cirrhosis, and its complication liver cancer. NAFLD is a major health problem and rapidly becoming one of the most common liver diseases worldwide. The prevalence of NAFLD in the general population of Western countries is 16-35% mainly due to the rapidly progressing epidemics of obesity and diabetes. The prevalence among obese people (body mass index more that 30kg/m²) in the United States has been reported as 80-90%. There is currently no pharmaceutical therapy approved for NAFLD and NASH are presently devoid of therapy ab@galmedgroup.com 2000 Chaim Hurvitz, Chairman Allen Baharaff, CEO Dr Maya Halpern, CMO

61 CONTACT Guoliang Fu Co-founder and CEO/CSO 71 Milton Park Abingdon Oxford OX14 4RX UK GeneFirst The company is supported by grant, investor and license. GeneFirst is a molecular diagnostics company, working in the fields of multiplex detection of infectious diseases and cancer diagnostics. GeneFirst offers simple, sensitive and affordable molecular diagnostics products - both established assays and bespoke co-development for novel targets. It has a rich portfolio of patented technologies, some of which have been advanced into products. Our major focus is: i) detecting and genotyping of all 14 high-risk HPV strains in a single, closed-tube PCR reaction; ii) detecting extreme rare cancer gene mutations in blood stream for early cancer diagnostics and companion diagnostics info@genefirst.com 2011 Dr Luke Alphey, Chairman Dr Guoliang Fu, CEO/CSO Mr Andrew Wood, CFO

62 CONTACTS Adrian Haigh COO Gentium GmbH Salvatore Calabrese CFO Serena Ramon Executive Assistant Gentium S.p.A From First Half 2013 Financial Results Press Release (August 13, 2013) Product sales were EUR million compared with EUR million, recording an increase of EUR 3.49 million, or 26%. Defibrotide net sales through the named-patient and cost recovery programs amounted to EUR million compared with EUR million, recording an increase of EUR 2.91 million, or 26%. Sales of the Company s active pharmaceutical ingredients (APIs) amounted to EUR 2.92 million compared with EUR 2.33 million, an increase of EUR 0.59 million, or 25%. Total revenues were EUR million compared with EUR million. Operating costs and expenses were EUR million compared with EUR million. Research and development expenses, which are included in operating costs and expenses, were EUR 6.91 million compared with EUR 5.19 million. Selling, general and administrative expenses, which are also included in operating costs and expenses, were EUR 5.56 million compared with EUR 5.95 million. Operating income was EUR 2.65 million compared with EUR 0.14 million. Pre-tax income was EUR 2.77 million compared with EUR 0.22 million. Net income/(loss) was EUR 2.65 million compared with EUR (0.09) million. Basic and diluted net income per share was EUR 0.18 and EUR 0.17, respectively, compared with a basic and diluted net loss per share of EUR (0.01). Piazza XX Settembre Villa Guardia (COMO) Italy (Serena Ramon) sramon@gentium.it 1993 as Pharma Research 2001 changed the name to Gentium S.p.A. Gentium S.p.A. (GENT - NASDAQ) is a biopharmaceutical company, headquartered in Villa Guardia (Como) - Italy, focused on research, development and manufacture of active ingredients derived from natural sources as potential therapeutic agents. Gentium s mission is to discover and provide new therapies to care-givers for diseases that currently have few or no treatment options with the aim to improve the lives of those faced with rare diseases with high unmet medical needs. Defibrotide, an investigational drug based on single-stranded DNA extracted from pig intestines, is Gentium s most advanced product candidate. In the U.S., Defibrotide has been granted orphan status by the Food and Drug Administration (FDA) for the treatment of hepatic veno-occlusive disease. In The EU, the European Medicines Agency (EMA) has granted Defibrotide orphan status for the prevention of hepatic veno-occlusive disease. Currently, Defibrotide is under development for the treatment and prevention of a rare disease called hepatic veno-occlusive disease, or VOD, a condition in which some of the veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation treatments, that are given prior to stem cell transplant. Severe VOD is the most extreme form of VOD and is associated with multiple-organ failure and high rates of morbidity and mortality. Currently, there are no approved treatments for VOD by either the U.S. FDA or EMA. Two pivotal Phase II/III clinical trials with defibrotide for the treatment and prevention of VOD have been completed, a Phase III trial for treatment of severe VOD in the U.S., Canada and Israel and Phase II/III pediatric trial in Europe for the prevention of VOD. In the absence of approved treatments for VOD, defibrotide has been made available as an investigational new drug, through a Treatment IND Protocol for patients with VOD (in the U.S.) and on a named patient basis in Europe. Dr Khalid Islam, Chairman of the BoD and CEO Mr Salvatore Calabrese, SVP Finance & CFO Mr Adrian Haigh, COO Gentium GmbH Mr Terenzio Ignoni, Vice President Quality Dr Carin Heringa, Senior VP and Scientific Director

63 CONTACTS Dr Dirk Groenewegen CEO Dr Jan Spanholtz Head of Research Onderwijsboulevard 219 PO Box DB s Hertogenbosch ) 1997 Glycostem Therapeutics Investment phase Investors are: 1. Management 2. Brabant Lifesciences Seed Fund 3. Start-up Fund Brabant Glycostem Therapeutics offers an innovative solution to eliminate cancer through Natural Killer (NK) cells. Glycostem produces NK-cells for cellular immunotherapy from umbilical cord blood (UCB) through a proprietary GMP-compliant platform technology. This technology enables ex-vivo generation of high numbers of very pure and highly activated NK-cells for clinical applications. These NK-cells offer a highly valuable addition to current treatments in order to prevent recurrence of cancer and can be effective in many different types of cancer. Glycostem s first experimental product has fulfilled the objectives of a phase I trial on elderly patients suffering from Acute Myeloid Leukemia. NK-cells actively migrated to the bone marrow and targeted leukemic cells. The 1st patient treated is meanwhile disease free since 21 months, which is a unique achievement. Overall results indicate NK-cell therapy to offer a solution for the hitherto unmet medical needs of AML-patients. In subsequent trials NK-cells will be applied in phase I/II evidence study s in Acute Myeloid Leukemia, Multiple Myeloma and EGFR+ solid tumors, such as colon-rectal, throat-neck, lung and breast tumor during 2014 and The company seeks investors for supporting the above. Dr Dirk Groenewegen, CEO Dr Jan Spanholtz, Head of Research

64 CONTACT Malcolm Weir CEO Heptares Therapeutics Ltd BioPark Broadwater Road Welwyn Garden City Hertfordshire AL7 3AX +44 (0) (dl) +44 (0) (m) +44 (0) Heptares Therapeutics Ltd To date, we have raised over $60 million in financing from Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, AstraZeneca, MedImmune, Morphosys, Cubist and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer s disease, Parkinson s disease, schizophrenia, addiction, headache disorders and diabetes. Our in-house pipeline is led by our selective muscarinic M1 programme for cognition in Alzheimer s disease and Schizophrenia, which is in preclinical development and slated for Phase 1 studies in late Our adenosine A2a antagonist candidate, which has been licensed to Shire, is also in development for neurological disorders. Further discovery programmes include oral GLP-1 agonists for T2DM, driven by our proprietary first-ever Family B crystal structure, and CGRP antagonists for prophylaxis and treatment of migraine and Cluster Headache. The Heptares technology platform represents a unique GPCR capability in the industry today, opening up new possibilities for both small molecule and antibody therapeutics across the GPCR target universe. Heptares is the first and only company transforming GPCRs, which are typically highly unstable when removed from cellular membranes, into stabilised receptors or StaRs. StaRs enable GPCR structures in their natural pharmacological conformations to be determined, thereby overcoming a major historical barrier to structurebased GPCR drug discovery. Heptares has also invented Biophysical Mapping, which provides superior elucidation of GPCR-ligand interactions, and has engineered new fragment-based and in silico technologies specifically tailored to GPCR lead discovery and optimisation. These technology breakthroughs, coupled with deep expertise in GPCR chemistry and biology, form the nucleus of a powerful and fully-integrated drug discovery platform. To learn more about the Heptares pipeline and technology platform, please visit Dr Malcolm Weir, Co-Founder and CEO Dr Fiona Marshall, Co-Founder and CSO Dr Barry Kenny, CBO Dan Grau, President Dr Miles Congreve, Vice President of Chemistry Dr David McGibney, CMO and Head of Development

65 CONTACT Juhani Lahdenperä CEO Hermo Pharma Ltd. Viikinkaari Helsinki Finland lahdenpera@hermopharma.com Hermo Pharma Ltd Not publicly available. Hermo Pharma Ltd is a clinical stage biopharmaceutical company discovering and developing cuttingedge therapeutic products and approaches for currently untreatable medical needs in the field of neurology. Company s headquarter is located in Helsinki, Finland. The company outsources the majority of operational R&D tasks to external vendors, while controlling the key technology assets and strategic partnerships. The company s R&D programs are based on scientifically innovative concepts. These concepts are being developed by the company through preclinical and clinical Phase II proof-of-principal trials and after that Hermo Pharma will seek partnerships to support Phase III trials and market its products worldwide. Currently Hermo Pharma s product development focus is on novel disease-modifying treatments for amblyopia in adults and Parkinson s disease. Amblyopia in Adults. The project is currently in Phase IIa clinical trials and the results seems very promising. Company is expecting to out-license this product latest in early Parkinson s Disease. Company is currently finalizing the pre-clinical proof-of-concepts studies with the support of M.J.Fox Foundation financing. The therapy is based on the neuroprotective and restorative effects provided by the CDNF protein. The clinical strategy includes of testing of intracrainial delivery platform to treat the patients. The current data looks very promising and the company is expecting to proceed into the IND enabling Toxicology phase during year Juhani Lahdenperä, CEO Henri Huttunen, CSO Sigrid Booms, Head of Clinical Development Board of Directors Jonathan Knowles, Timo Veromaa, Ari-Pekka Laitsaari, Henri Huttunen Jyrki Mattila Scientific Advisory Board Eero Castrén Mart Saarma Mary Baker Seppo Kaakkola Lamberto Maffei Heikki Rauvala Pekka Männistö.

66 CONTACTS Christoph von Keudell CEO Bruno Odermatt CFO HFM-AG Wagistrasse 23 CH-8952 Schlieren HFM Hybrid Fusion Medicals AG HFM is developing with state-of-the-art scientific and innovative early market entry strategies plant-derived prescription drugs in oncology (e.g. lymphedema after breast cancer), virology (non-responders in chronic Hepatitis C including advanced liver diseases), (auto)-immune diseases and CNS (Parkinson). HFM identifies, patents and develops plant-derived pharmaceuticals in areas of high medical need. We are merging the human race medical knowledge bases from different continents developed during high civilizations in the evolution of mankind with latest biotech tools and clinically driven highly innovative IT platforms. This includes also the integration of broad based molecular tools and other data bases for implementing 22nd century personalized medical technologies in our drug development. We are entering global markets with our first two products in Christoph von Keudell, M.D.Ph.D, CEO & Chairman of the Board Bruno Odermatt, CFO Gaby Wiederkehr, VP Global Regulatory cvk@hfm-ag.org bo@hfm-ag.org 2013

67 CONTACTS Mark Bleckmann Director & Head of Finance Nikola Wiegeler Communications immatics biotechnologies GmbH Paul-Ehrlich-Straße Tuebingen Germany immatics biotechnologies GmbH immatics successfully concluded a total of three financing rounds, raising a total of 108m. The company is backed by a particularly strong investor group, comprised of family offices and VCs. immatics is a clinical stage biopharmaceutical company, active in the field of cancer immunotherapy. immatics is developing TUMAP-based (=Tumor Associated Peptides) therapeutic vaccines that are active against cancers with a high unmet medical need. Three product candidates, all of which were developed with its proprietary technology platform XPRESIDENT are currently in clinical development. Phase II results from its products IMA901 in RCC and IMA910 in CRC showed a correlation of the number of peptides that patients responded to and the clinical benefit these patients experienced. The furthest advanced product, IMA901 in RCC, is presently in a clinical Phase III trial, which is fully recruited. All of immatics current products are off the shelf products. Please visit our website at to find out more about immatics. Paul Higham, CEO Harpreet Singh, CSO Carsten Reinhardt, CMO Rainer Kramer, CBO

68 CONTACT Bernhard Sixt President & CEO 7 parvis Louis Néel CS Grenoble Cedex 9 France ImmunID (0) bsixt@immunid.com contact@immunid.com 2005 ImmunID is pioneering the field of molecular immune diagnostics since 2005, offering two commercial products. Its proprietary CE-marked flagship product ImmunTraCkeR evaluates the T cell receptor repertoire diversity at the genomic level. The company is ISO9001 certified and runs an ISO13485 accredited research and production facility in the MINATEC high-tech campus in Grenoble, France, and provides research and testing services worldwide to leading clinical centers and blue-chip pharmaceutical companies such as Roche and Sanofi- Pasteur. Bernhard Sixt, President & CEO Sébastien Weisbuch, COO & Co-Founder Nicolas Pasqual, CSO & Co-Founder Nadia Plantier, VP Business Development Jean-François Mouret, CTO

69 CONTACT Dr Philippe Guedat Managing Director INFLECTIS BIOSCIENCE Parc de la Chantrerie 95 route de Gachet Nantes cedex 3 FRANCE +33 (0) InFlectis BioScience Looking for seed funds : Dr Guedat was awarded Lauréat national, Emergence Concours national d aide à la création d entreprise innovante InFlectis BioScience (IB) is a private drug discovery company developing small molecule drugs that specifically target Unfolded Protein Response (UPR) to treat neurodegenerative and age-related diseases. IB s drugs aim at reducing endoplasmic reticulum (ER) stress by promoting correct folding of proteins, improving the efficiency of ER associated degradation and/or enhancing the detection of misfolded proteins, thus being useful in delaying or preventing neurodegenerative and/or age-related diseases. IB s IFB-088 is a first-in-class orally available product candidate in late preclinical development stage targeting UPR to treat neurodegenerative diseases (Charcot-Marie-Tooth & Retinitis Pigmentosa). IFB-088 has a validated mechanism of action and has an excellent safety and efficacy profile. This project is supported by robust scientific program which was published in Science (2011) by A. Bertolotti (MRC, Cambridge UK), InFlectis BioScience co-founder. With its unique drug discovery platform InFlectis BioScience is also developing additional compound family s drug candidates to go through several approvals for non-orphan indications to treat age-related diseases (such as Parkinson disease, Huntington disease ). Philippe Guedat, PhD, Managing Director Philippe has 17 years of Drug Discovery experience. He led Drug Discovery at Vivalis from 2008, where he developed anti-hcv molecules and the 3D-Screening technology. Prior to Vivalis, he was Director of Chemistry at Hybrigenics (Paris, France), focusing its interest on Protein-Protein Interaction and the discovery of the first Ubiquin-Specific Protease inhibitors in oncology. Philippe started his career in 1998 as a Research Assistant at Cambridge University and SmithKline Beecham (Harlow, UK) before joining Merck KGaA as Medicinal Chemist and Discovery Project Leader working on the dyslipidemia field. Anne Bertolotti, PhD, (Scientific Director for UPR Scientific Adviser) Anne has been a group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK since 2006, where she is looking at strategies that can help cells boost their natural defenses against misfolded proteins. Prior to this, Anne was Associate Professor at Ecole Normale Supérieure (INSERM) and was awarded an EMBO Young Investigator award in In 2013, Anne was nominated EMBO member.

70 CONTACTS Dr Greg Collier CEO & Managing Director Ms Melanie Farris Unit 2, 120 Bluestone Circuit, Seventeen Mile Rocks QLD 4073 Australia Invion Limited Market capitalisation: A$42.1 as at 12 Sept 2013 Cash in bank: A ~$3 M as at 30 June 2013 Anticipated R&D tax rebate cash inflow: $1.46M Cash burn (12 months to 30-June-13) ~$6M Invion is a clinical-stage life sciences company focussed on the development of treatments for major opportunities in the inflammatory diseases market including asthma and COPD ($34B) and systemic lupus erythematosus (lupus) (to $4B). Invion has two drug assets in three FDA-regulated, phase II clinical trials currently underway in the US. INV102 (nadolol) is a beta blocker (beta adrenergic inverse agonist) currently used in the treatment of high blood pressure and migraine that is being repurposed to treat chronic inflammatory airway diseases (e.g. asthma and COPD). Data from completed phase II trials has demonstrated acceptable safety and dose-dependent airway responsiveness. Early data led to the US National Institutes of Health funding Invion s phase II asthma clinical trial in excess of USD$4M, and a second phase II trial in chronic bronchitis is also now underway. INV103 (ala-cpn10) is a modified naturally occurring human protein shown to reduce IL-6, a key marker in the chronic inflammatory disease, lupus. Data from Invion s phase II lupus clinical trial is anticipated late in Invion has an experienced management team in Managing Director & CEO Dr Greg Collier (former ChemGenex CEO), and Executive Vice President R&D and Chief Medical Officer, Dr Mitchell Glass (5 drugs approved with FDA). investor@invion.com.au Invion was formed through a merger in August 2012 Dr Greg Collier, Chief Executive Officer and Managing Director Dr Mitchell Glass, Chief Medical Officer

71 CONTACTS Kayla Parcells Caitlyn Murphy Angeli Kolhatkar 135 Beaver St., Suite 309 Waltham, MA Kala Pharmaceuticals Kala Pharmaceuticals is advancing innovative treatments for ocular diseases based on a proprietary platform to deliver therapeutic agents across mucus barriers. Kala s Mucus Penetrating Product ( MPP ) platform technology facilitates penetration into target tissues, such as the retina, following topical eye drop delivery. MPP technology can enable delivery of a diverse array of small molecule compounds to treat a variety of ophthalmologic indications (e.g., post-operative inflammation, dry eye, blepharitis, diabetic macular edema (DME), and wet agerelated macular degeneration (AMD)). Kala s most advanced program is an MPP formulation of loteprednol etabonate ( LE-MPP ) to treat post-surgical ocular inflammation and pain. A registration study for this indication will commence under a US IND in The Company also will initiate clinical trials in the U S of LE-MPP in dry eye, blepharitis, and DME in Further, a research phase program involving a topically applied RTKi is advancing toward selection of a product candidate in 2014 for the treatment of wet AMD info@kalarx.com Kayla.Parcells@kalarx.com cmurphy@burnsmc.com akolhatkar@burnsmc.com Guillaume Pfefer, PhD, MBA, President and CEO Kim Brazzell, PhD, Chief Medical Officer Charlie McDermott, Executive Vice President, Business Development

72 MEDICENNA THERAPEUTICS, INC. CONTACT Dr Fahar Merchant, Ph.D President and CEO West Georgia Street Vancouver, BC Canada V6E 3C Medicenna Therapeutics, Inc. Privately held. 100% Management owned Medicenna, is a clinical stage privately held, virtual company led by a team of experienced executives and advisors. With a promising Phase II program for recurrent glioblastoma multiforme (GBM), Medicenna is taking the lead in developing first- and best-in-class Empowered Cytokines (ECs). These fusion proteins are designed to harness the targeting specificity of Superkines (engineered cytokines) to selectively deliver cell-killing agents in order to simultaneously ablate the bulk tumour, the pro-tumour micro-environment and cancer stem cells. MDNA55, our lead drug, is a patient-centric therapy targeting at least a dozen different cancers in patients with an IL-4/IL-4R bias. MDNA55 has received Fast Track Designation for the treatment of recurrent glioma by the FDA and has been granted Orphan Drug Status by EMA and FDA. In addition, our exclusive licenses from Stanford, Hebrew University of Jerusalem and NIH, enables us to deploy our platforms to generate Empowered Cytokine and Superkine versions of Proleukin, Leukine and Ontak, providing Medicenna the ability to extend its pipeline with less risk. fmerchant@medicenna.com 2011 Fahar Merchant, Ph.D. President and CEO Formerly President and CEO, Sophiris Bio (Nasdaq SPHS); President and CTO, KS Biomedix; President and CEO, Avicenna Medica. Samuel Denmeade, MD. Chief Scientific Advisor Professor of Oncology, Johns Hopkins University; Scientific Founder and Former CSO, Sophiris Bio, Scientific Founder, Genspera, Inc. Ralph Smalling, M.S. Regulatory Advisor Principal, Linus Consulting; Former VP Regulatory Affairs, Amgen. Rosemina Merchant, M.Sc. CDO Former SVP of Development and RA, Sophiris Bio; Management positions at KS Biomedix; Intelligene Expressions; Bioniche; GE Healthcare; Sanofi Canada Shafique Fidai, Ph.D. Head of Discovery and Corp Dev Formerly VP of Corp Dev, Sophiris Bio; VP of BD, Chromos; Director of BD, Xenon Pharm.

73 CONTACTS Eduardo Margallo President & CEO Medlumics S.L. Ronda de Poniente 16 1E Tres Cantos SPAIN MedLumics S.L. MedLumics is currently seeking a B-Round of 11M to support its expansion from 2014Q2. These funds take the company to break-even in 2017 and have two main application areas: The commercial launch in 2014H2 of a dermatology imaging product providing high resolution information of the skin to support first-line diagnostics and therapy guidance, and the development, clinical validation and commercial launch of an RF Ablation catheter Medlumics reaches break-even in 2017 with fast-growing revenues in the last two years of operations. Sales in dermatology accelerate the launch of the guided RF ablation line, minimizing capital needs, reducing company risk, staging market access and improving scalability into a high upside market. Guided by OCT in Eduardo Margallo investors@medlumics.com emargallo@medlumics.com 2011 MedLumics is a diagnostic imaging company developing a new generation of portable clinical systems that generate high resolution images of tissue. These devices are based on optical coherence tomography (OCT), an established imaging modality in ophthalmology with fast growing applications in other fields of medicine. The company has developed an optical chip that allows a radical reduction in system size and complexity while offering unprecedented image features. Its unique technology also supports novel catheter designs. MedLumics is actively developing a first-in-class hand-held device for the diagnosis of skin tumors using OCT information. This opportunity represents a market of 180M$/yr. The product is expected to launch in the second half of 2014, providing high-quality OCT at a price compatible with broad adoption. By incorporating standard epiluminescence microscopy, it allows for seamless integration with current clinical workflows. In parallel, MedLumics is developing an OCT-guided RF ablation catheter for use in atrial fibrillation management. With an opportunity exceeding 1.3B$/yr., the target launch date for this product is 2015Q3. MedLumics unique catheter design shall provide accurate monitoring of energy delivery to tissue and direct visualization of lesion size and continuity, thus reducing recurrence rates and procedure time. Eduardo Margallo, PhD, President & CEO Pioneer in the photonic integration of optical coherence tomography (8+ yr. experience) and with a strong background in business administration and management. Jose Luis Rubio, PhD, CTO Expert in medical imaging (8+ yr. experience) with a deep understanding of the challenges and potential of integrated optics for optical coherence tomography, and an specialization in IP and innovation management. Miguel Eslava, COO Ex-general manager at GE Healthcare for Spain and Portugal, with a strong international business network and a solid experience (over 30yr.) in operations, quality management and team leadership. Pedro Oliveira, Marketing Manager Over 10yr international experience in Business Development and Product Management at J&J. Lucía Colmenero, Finance Manager Solid experience in financial management of technology start-ups.

74 CONTACTS Michael Scherz Founder & Chief Executive Officer Patrick Scherrer Lead Financial Advisor Steinenring 8 CH-4051 Basel Metys Pharmaceuticals CHF as name shares at CHF 1.00 per share. Investment Objectives Seed investment round, up to CHF Series A investment round, up to CHF Metys Pharmaceuticals signed an Option Agreement on 10 June 2013 with Neurotune AG, Schlieren, ZH, Switzerland, giving Metys exclusive world-wide option for all indications to dimiracetam and related compounds. Dimiracetam is a small molecular weight drug of the racetam class, in clinical development for the treatment of neuropathic pain. In animal models the compound has an efficacy profile superior to pregabalin (LyricaTM) and other prominent anti-neuropathic agents. Dimiracetam has completed healthy subject testing as well as a safety- & tolerability-study in HIV patients. Metys is preparing the first dedicated efficacy study of dimiracetam in HIV-associated painful neuropathy. Dimiracetam is protected by method-of-use patents granted in major markets, and other patent applications granted or pending. Metys is also entered a successor compound into preclinical development for the treatment of neuropathic pain, including neuropathic pain of osteoarthritis. Michael Scherz Patrick Scherrer michael.scherz@metys-pharma.ch patrick.scherrer@metys-pharma.ch 2013 Michael Scherz, CEO & Founder formerly Vice President, Life Cycle Management, Actelion Pharmaceuticals Patrick Scherrer, Lead Financial Advisor formerly CEO, Widmann Associates

75 CONTACT Philippe Mauberna CFO NANOBIOTIX 60 rue de Wattignies Paris France +33 (0) (0) Nanobiotix Public company Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy and brachytherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France. Nanobiotix is listed on the NYSE Euronext regulated market in Paris (ISIN: FR , Euronext ticker: NANO, Bloomberg: NANO: FP). Laurent Levy, CEO Elsa Borghi, CMO Philippe Mauberna, CFO Bernd Muehlenweg, CBO 2003

76 CONTACT Stefan Weber CEO via Ludovico Ariosto, Bresso (Milan) Italy stefan.weber@newron.com ir@newron.com 1999 Newron Pharmaceuticals S.p.A Newron raises e18.5 million from Atlas Venture and 3i Group plc in an initial closing of B Round. Newron expands B round financing to e25 million Apax Partners invests e6.5 million in second closing 2005 Newron completes e30 million Series C Financing 2006 Newron IPO on the SWX Swiss Exchange raises e74.3 million 2008 Newron awarded EUR 5 million by the Italian government for R&D and training support 2009 Newron raises CHF 7.9m in a private placement to international institutional investors 2010 Newron raises CHF 3.5m through a private placement to Great Point Partners, LLC 2011 Newron receives EUR 3.7million under Italian government R&D support program 2012 Newron enters in license agreement with Meiji Seika Pharma and Zambon for safinamide Newron raises CHF 4.7m through a private placement 2013 Newron receives e2.5m Strategic Translation Award from Wellcome Trust to develop experimental drug candidate for ALS. Newron places new shares under the up to 10% share capital increase Newron Pharmaceuticals S.p.A. is an international biopharmaceutical company focused on the development of novel therapies for diseases of the Central Nervous System (CNS) and pain, to improve patients quality of life. Newron has a promising pipeline of highly innovative compounds. Our lead product, safinamide, has completed phase III development for the treatment of Parkinson s disease (PD) and is expected to be filed with the US and European regulatory authorities during Q4/2013. Safinamide is partnered with Meiji Seika Pharma Co., Ltd., a subsidiary of Meiji Holdings Co., Ltd., in Japan and key Asian territories, and with Zambon Group in all other markets including the US and Europe. Newron s other projects are primarily focused on treatments for rare CNS diseases and are at various stages of preclinical and clinical development. These include snn0031 for Parkinson s disease, sarizotan for Rett s syndrome, snn0029 for ALS, ralfinamide for specific pain indications, and NW-3509 with potential as the first add on therapy for the treatment of schizophrenia. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a clinical development site in Basel and an R&D site in Stockholm. The Company is listed on the SIX Swiss Exchange, trading symbol NWRN. Stefan Weber, Chief Executive Officer Marco Caremi, Executive VP Business Development Ravi Anand, Chief Medical Officer Roberto Galli, VP Finance Anders Haegerstrand, General Manager NeuroNova AB

77 CONTACTS Didier Toubia CEO Merav Saimon Administrative Manager 6 Yad Harutzim St. Kefar Saba Israel NLT SPINE Ltd. Raised $15.5M to date 2012 Revenues: $35,000 (pilot launch) NLT SPINE Ltd. is committed to lead Minimally Invasive Surgery (MIS) revolution in Spine by developing innovative procedures based on its proprietary platform technology, with the goal of improving surgery outcomes and reducing the associated treatment cost. While 70-80% of the spine surgeries are still open and cause significant trauma to the patient, the company s vision is to radically change the way spine surgery is performed, leading an Industry revolution similar to the way cardiovascular procedures have shifted from open surgery to catheter-based surgery. NLT SPINE s products are based on its proprietary non-linear platform technology that enables the insertion of large implants and instruments into the spine through a small incision. NLT SPINE s first two products PROW FUSION interbody implant, and espin discectomy instrument (both cleared by the FDA),may be either used separately, or smoothly integrated to provide a full lumbar interbody fusion procedure, a gold-standard procedure where two vertebrae are fused to restore spine stability and treat pain associated with degenerated discs. Feedback from initial launch in 2012 has been positive and the company is currently preparing for a commercial roll-out phase. Leveraging its powerful platform technology, the Company plans to launch a total of 6 products in (including other devices for interbody fusion, the ARC pedicle screw, etc), targeting all the major segments of the global $7.6 billion a year spinal implant market. The regulatory paths for these products are 510(k) in the US, enabling a relatively quick penetration of the world s largest market. NLT SPINE is headquartered in Israel with offices in Boston, MA Merav.s@nlt-spine.com Didier.t@nlt-spine.com 2007 Didier Toubia, Chief Executive Officer Dr. Tzony Siegal, Founder and Chief Medical Officer Avi Shterling, Chief Operation Officer and R&D Director Oded Loebl, VP Technologies Tom Keegan, VP Business Development and U.S. Marketing Eti Zinger, VP Regulatory Affairs & Quality Assurance Orly Schwartz, Clinical Director Ada Gutgold, HR Manager

78 CONTACTS NOXXON Headquarters Emmanuelle Delabre NOXXON Business Development Aram Mangasarian, PhD Chief Business Officer NOXXON Pharma AG Max-Dohrn-Strasse Berlin Germany edelabre@noxxon.com amangasarian@noxxon.com 1997 NOXXON Pharma AS NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers*, the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics: anti-ccl2/mcp-1 Spiegelmer NOX-E36 for diabetic nephropathy anti-cxcl12/sdf-1 Spiegelmer NOX-A12 for oncology anti-hepcidin Spiegelmer NOX-H94 for anemia of chronic disease The Spiegelmer platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a mature, well-financed biotech company with a strong syndicate of international investors, and approximately 60 employees. Executive Board Iain Buchanan, CEO (since 2010, joined the board of directors in 2007) Dr Matthias Baumann, CMO (since 2011) Dr Sven Klussmann, CSO, co-founder of NOXXON (since 1997) Aram Mangasarian, PhD, CBO (since 2010) Chairman of the Supervisory Board Dr Walter Wenninger (since 2007)

79 CONTACT Oliver Middendorp CBO and Co-CEO Numab AG Einsiedlerstrasse 34 CH-8820 Wädenswil Switzerland Numab AG The Company is financed through its collaboration revenues. Numab is a privately owned Swiss biotech company focusing on the discovery and development of antibody fragment-based therapeutics. The 13 people Company being operational since January 2012 has signed two revenue-generating industry collaborations and is currently moving its first proprietary bi-specific lead molecule into preclinical development. Numab s lead product (ND007) is being developed for the treatment of severe chronic inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis or inflammatory bowels disease (IBD). ND007 exploits a novel mechanism of action to specifically eliminate the disease-causing, autoreactive T cells by means of a bi-specific anti-cd3xil23r antibody fragment. This approach carries the promise for better efficacy, longer effect duration and better safety as compared to standard of care biologics. Numab is led by a Management with proven track record in the biotech industry (4 out of 5 Management members have been long lasting employees in key positions at ESBATech). Numab applies proprietary breakthrough technology that allows for fast and reproducible discovery of best-inclass antibody fragment based therapeutics. The technology is used to broaden Numab s proprietary pipeline and for discovery partnerships with the pharmaceutical industry. The Company is currently looking to raise CHF 11 million in a Series A to expedite its lead program to its first clinical trial application (CTA) by mid o.middendorp@numab.com 2011 David Urech, PhD, CSO & Co-CEO Oliver Middendorp, PhD, CBO & Co-CEO Tea Gunde, PhD, Head of Pharmacology Sebastian Meyer, PhD, Head of Biochemistry Roland Helfenstein, Head of Finance and Administration

80 CONTACT Anna Yanaeva Business Development Assistant 8/2 Bolshaya Moskovskaya let-a, suite 4-1 Saint Petersburg, Russia +7 (812) (812) OCT Turnover in e OCT is a leading mid-size contract research organization (CRO) in Russia, CIS and Central and Eastern Europe. With more than 90 people on staff, OCT provides drug development services to its clients. OCT clients and partners include pharmaceutical, biotechnology, medical device and non-for-profit organizations. Since 2005 OCT has been involved in a number of clinical trials programs which were placed in Russia, Ukraine, Bulgaria, Belarus, Latvia, Lithuania and Estonia. OCT provided program management and clinical development services for Phase I-IV clinical trials, as well as pre-clinical and bioequivalence studies. We advance a product through development and approval on time and within a client s budget. Our experienced teams deliver quality results for our clients drug research and development needs which may vary from full clinical trial program to standalone CRO service like medical writing, consultancy, monitoring, data management or statistics. OCT expertise includes more than 150 projects in a wide range of therapeutic areas, including but not limited to oncology, cardiology, pediatrics, endocrinology, ophthalmology and others. ayanaeva@oct-clinicaltrials.com 2005 Dmitry Sharov, President Elena Startseva, Head of Business Development Irina Petrova, Clinical Operations Director

81 CONTACT Dr Sanja Selak CEO Leberstrasse 20 A-1110 Vienna Austria Origimm Series A fund raising Origimm is a young ambitious Austrian biotech company striving to become a market leader in protective antigen discovery. Using its proprietary ProVaDis technology platform Origimm supplies its candidates to industry pipelines for innovative vaccine and immune therapy development. Origimm s first product is the innovative, first therapeutic vaccine against acne vulgaris. Our vision is to bring innovation in the vaccine discovery and establish ourselves as a prime research oriented biotech company supplying pipelines of pharmaceutical companies, as well as developing our own products. We strongly believe that best quality, most protective vaccine antigens represent the essence or the Origins of Immunity (hence the name, Origimm). Our mission is dedication and purity in science for saving and improving people s lives, under the highest ethical standards. Origimm was founded by Dr. Sanja Selak former Head of Department of Serology and Immune Assays at Intercell. It is now entering the seed phase backed up by Austrian governmental institutions. For more information please visit Dr Sanja Selak, CEO Mag Thomas Fischer, Finance Manager Dr Anthony Sedgwick, Chairman

82 CONTACTS Carlos Buesa CEO Emili Torrell BDO C/San Ferran Cornella de Llobregat (Barcelona), SPAIN ORYZON Stage of funding 5 Funding rounds from inception (15 M in total) + 15 M in Competitive Grants. Last funding (9M ) was accomplished in These funds were also matched with a set of competitive grants and long-term / nullvery soft rates public loans. Capital plans IPO plans The Company will need a new round of funding (15M) in late 2013 early 2014 to keep the development of the programs to Phase I-II in full speed and to achieve PoC by the end of Investors. The company has a French-Spanish VC firm NAJETI as main stakeholder from Other VCs having minor stakes are CORSABE, Invercat and Barcelona Empren. Several Spanish family offices and private minor investors are also present. Oryzon is a biopharmaceutical EPIGENETIC company with a strong focus in Histone Lysine Demethylases. We are a global leader on Lysine Specific Demethylase-1 with a dominant IP position (18 patent families, 1 patent already granted in US). LSD1/KDM1A has been proposed as a target for oncology, viral diseases and neurodegeneration. Oryzon s therapeutic pipeline is strongly focused in oncology. The company is starting now its first Clinical TRIAL Phase I/IIA in Acute Leukemia in UK and Spain with its first molecule ORY This LSD1/KDM1A inhibitor is highly potent in vitro and in vivo and shows exquisitely selectivity and has been granted orphan-drug status by the EMA. The company is raising 15M Euro to complete Clinical studies till Phase IIB. Oryzon has another LSD1/KDM1A program in Alzheimer ready to enter in IND enabling tox. The Diagnostic activities have been allocated in an independent Diagnostics company and the preclinical research has been finalized. The company has now a reduced head-count to lead the clinical development of the programs cbuesa@oryzon.com etorrell@oryzon.com info@oryzon.com 2000 Carlos Buesa, Chief Executive Officer PhD in Biochemistry and Molecular Biology at the University of Barcelona (UB) in Spain. In 2000, he founded Oryzon and since 2001 he has served as Chief Executive Officer and Chairman of the Board of Directors. In addition, he sits on the board of other biotech companies He has taken the executive education programme (PADE) at the IESE Business School. He is also boardmember of Inveready Capital, a specialized Seed VC.

83 CONTACTS John Dawson, CEO* Tim Watts, CFO (presenting) Lara Mott, Head of IR* *not in attendance Oxford BioMedica Medawar Centre Robert Robinson Avenue The Oxford Science Park Oxford OX4 4GA +44 (0) John Dawson +44 (0) Tim Watts +44 (0) Lara Mott +44 (0) (0) , listed December 1996 (AIM), moved to LSE main market April 2001 Oxford BioMedica plc audited financial results: Revenue 7.8m (2011: 7.7m) R&D costs of 14m (2011: 17.8m) Net loss of 8.7m (2011: 12.6m) Net cash burn of 10.5m (2011: 16.5m) Net cash of 14.1m as at 31 Dec 2012 (2011: 14.3m) At 30 April 2013, the Company had a net cash1 balance of 9.2m (unaudited). Including income from the Novartis collaboration (announced May 2013), the Company has sufficient cash resources to fund operations into Q Oxford BioMedica is one of the leading companies in gene therapy and immunotherapy with a platform of exclusive and pioneering technologies to design, develop and manufacture unique gene-based medicines. Our pipeline addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular diseases, neurodegenerative disorders and cancer, and our product candidates have the potential to transform treatment landscapes. Through our in-house development programmes and collaborations with leading industry partners, our goal is to improve the lives of patients with debilitating and life-threatening diseases. Led by John Dawson, Chief Executive Officer, Oxford BioMedica s management team has strong experience in research, clinical development, intellectual property management, manufacturing, business development, due diligence and finance. Executive Directors: John Dawson, CEO Cephalon, Serono, establishment of revenue generating business & buy and build (Cephalon Europe) Leadership & strategy, business development Tim Watts, CFO AstraZeneca, Archimedes Pharma, over 20 years industry experience Financial management, strategic implementation Peter Nolan, SVP Commercial Development 16yrs at Oxford BioMedica. IP management, successful litigation history In/out-licensing, collaborations & legal issues, IP strategy Supported by commercial non-executive team Nick Rodgers, Andrew Heath, Paul Blake, Martin Diggle

84 CONTACT Ralf Penner Martinstrasse Aachen Germany PAION AG : Revenues 26,812 R&D -3,251 G&A -4,709 Result 16,009 EPS 0.63 PAION AG is a publicly-listed biotech company headquartered in Aachen, Germany with a second site in Cambridge, UK. The company has a track record in developing hospital-based treatments for which there is substantial unmet medical need. PAION AG is transforming its business model from a pure development company to a specialty pharmaceutical company with a focus on anaesthesia products to take advantage of the unique profile of its main compound, Remimazolam. r.penner@paion.com 2000 Dr Wolfgang Söhngen, Chief Executive Officer PhD, Diploma in Pharmaceutical Medicine (DGPharMed) and Master of Business Communication Founder of PAION Deutschland GmbH (2000) and PAION AG (2004) Over 20 years experience in drug development and strategic planning at globally operating pharmaceutical companies Dr Mariola Söhngen, Chief Medical Officer PhD, Diploma in Pharmaceutical Medicine (DGPharMed) and Master of Business Communication Co-founder of PAION Deutschland GmbH (2000) and PAION AG (2004) Over 20 years experience in clinical development, licensing and strategic project evaluation at globally operating pharmaceutical companies

85 CONTACTS Dr Franz Obermayr CEO Dr Stefan Sperl COO Parkring Vienna Austria Panoptes Pharma Panoptes is funded by private equity and obtained 1 million e interest free seed financing from the Austria Wirtschaftsservice. By end of 2013 Panoptes intends to conclude a series A financing round to enable completion of pre-clinical studies and first in man clinical studies by 2014/2015. Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. The development of Panoptes clinical candidate PP-001 focuses on a new treatment for autoimmune uveitis, a disease which is one of the major causes of blindness. As a second indication, adenoviral conjunctivitis will be pursued, a disease for which to date, no treatment is available. Due to its unique mode of action, PP-001 has therapeutic potential for additional inflammatory and viral indications. Panoptes has an experienced team of development experts with a proven track record of developing and commercializing innovative products. The team is developing a focused portfolio of high-performance small molecule products, with its lead clinical candidate PP-001 in preclinical development. Panoptes aim is to generate future growth by achieving major development milestones and by entering into partnerships with leading pharmaceutical companies. We believe the combination of our technology and costefficient development strategy will help ensure a rapid and more predictable path to commercialization, and has the potential of making needed therapies available to more patients Dr Franz Obermayr, Co-founder and CEO Previously he was Head of Clinical Development at Nabriva Therapeutics. His earlier career involved various positions at GPC- Biotech - most recently as Principle Scientist and Director Discovery. He completed his postdoctoral studies at the Max-Planck Institute for Immunobiology in Freiburg. Dr. Franz Obermayr earned his PhD in Biochemistry at the Imperial Cancer Research Fund in London in Dr. Stefan Sperl, Co-founder and COO Prior to this position he was global Project Manager at Nabriva Therapeutics AG, responsible for all development programs ranging from early preclinical to clinical phase 2 programs. Before that he headed the project management at Biovertis AG. From 2000 to 2005, Dr. Sperl headed the small molecule research unit at Wilex AG, where he was responsible for lead optimization and GMP production. Dr. Stefan Sperl received his PhD in Chemistry from the Max Planck Institute in Martinsried, Germany in 2000.

86 CONTACTS Gaël L Hévéder Head of BD Bernt-Olav Røttingsnes CFO Per Walday CEO Strandveien 55 N-1366 LYSAKER Norway PCI Biotech IPO 2008, raised MNOK 60 at NOK 20 per share Share issue 2010, raised MNOK 90 at NOK 40 per share Cash of MNOK 60 at end of Q PCI Biotech is a clinical stage cancer-focused company listed on the Oslo Stock Exchange. The company is developing a product that induces photochemical internalisation (PCI) of a wide array of modalities; e.g. small molecules, ADCs, and sirna; this patented therapeutic approach delivers drugs through triggered endosomal release. PCI Biotech s primary focus is localised treatment of cancer, with two programmes in clinical development: head & neck cancer (Phase II) and cholangiocarcinoma (Phase I/II). The PCI technology can also be used as an adjuvant platform for therapeutic and prophylactic vaccination. It has been demonstrated both in vivo and ex vivo that PCI can dramatically increase the number of activated Killer T-cells by enhancing the MHC I antigen presentation of antigen presenting cells. Per Walday, Chief Executive Officer Bernt-Olav Røttingsnes, Chief Financial Officer Anders Høgset, Chief Scientific Officer Gaël L Hévéder, Head of Business Development post@pcibiotech.com 2000 (subsidiary to the pharmaceutical company Photocure until 2008)

87 CONTACTS Dr Claus Kremoser CEO Thomas Hoffmann CFO Phenex Pharmaceuticals AG Donnersbergweg Ludwigshafen Germany Phenex Pharmaceuticals AG 22 Mio. Euro raised in four financing rounds. Phenex Pharmaceuticals AG is a drug discovery and development company with a focus on chronic inflammatory and liver diseases. Phenex preclinical RORg program was recently partnered with Janssen in a deal valued at 135 M USD. Phenex FXR agonist Px-104 has just entered a phase IIa clinical trial in patients with NAFLD/NASH. Phenex plans to raise additional money to demonstrate proof of principle in NASH and one more liver disease indication prior to going for an IPO or to partnering the program with a major pharma company. Dr Claus Kremoser, CEO Thomas Hoffmann, CFO info@phenex-pharma.com 2002

88 CONTACTS Dr Vladimir Cmiljanovic CEO Gaudenz von Capeller CFO PIQUR Therapeutics AG Mattenstrasse 24A CH-4058 Basel Switzerland PIQUR Therapeutics AG PIQUR is a biotech company focused on the discovery and the development of innovative, targeted anti-cancer drugs based on PI3K (phosphoinositide 3-kinase) and mtor (mammalian target of rapamycin) inhibition, two of the most promising therapeutic targets in oncology. While mtor is a clinically validated drug target, PI3K inhibition achieved clinical proof of concept status in Phase-III. PIQUR s efforts concentrate on the development of best-in-class small molecular weight molecules with dual inhibition, e.g. of both, mtor and PI3K. Generally, the combined balanced inhibition appears to be more efficacious than the inhibition of either target alone. Furthermore PIQUR s dual inhibitor PQR 309, jointly discovered and developed entirely by today s PIQUR team members, differentiates itself from other existing dual inhibitors through proven brain permeability, better drug properties and toxicological profile. PIQUR has raised CHF 5 million in 2012 and 2013 and has successfully completed toxicology studies in rats and dogs for its most advanced compound PQR309. It is planned to enter Phase-I (safety testing in human beings) in Q1/2014, for which PIQUR is raising between 7 and 11 Mio CHF. PIQUR will divide Phase-I into two Phases, IA and IB, including efficacy studies most often related to Phase-II, and will thereby gain significant amounts of time and data. The funds raised in this Series A financing round will mainly be destined to Phase-IA. As mtor and PI3K inhibitors have reached clinically validated drug target and proof of concept status, respectively, PIQUR is optimistic to provide considerably reduced investment risk as compared to other early stage biotech companies as well as highly interesting exit options for the investor in the next one to three years. Dr Vladimir Cmiljanovic, Chief Executive Officer Gaudenz von Capeller, Chief Financial Officer Doriano Fabbro, Chief Scientific Officer Frances Betts, Chief Development Officer Richard Herrmann, Chief Medical Officer Hervé Girsault, Chief Business Development & Licensing

89 CONTACTS John Burt CEO Neil Butt Business Development 2 Royal College Street, London NW1 0NH UK PolyTherics Ltd million financing round (July 2013) in connection with merger of PolyTherics with Antitope. PolyTherics investors include: Imperial Innovations Invesco Perpetual Mercia Fund Management Advantage Enterprise & Innovation Fund ProVen Growth & Income VCT Longbow Capital The Capital Fund PolyTherics provides technology solutions to enable the development of better biopharmaceuticals and offers a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. PolyTherics portfolio of proprietary services and technologies includes: Site-specific conjugation technologies: ThioBridge for homogeneous, stable ADCs TheraPEG, HiPEG, CyPEG for site-specific pegylation PolyPEG as a low viscosity alternative to PEG for half-life extension Immunogenicity assessment itope/tced In silico identification of T-cell epitopes EpiScreen human ex vivo assays for assessment of CD4+ T cell responses to peptides, proteins and antibodies Deimmunisation Composite Human Antibodies humanized, non-immunogenic antibodies through T cell epitope avoidance Composite Proteins re-engineered non-immunogenic therapeutic proteins through removal of T cell epitopes Manufacturing cell line development PolyTherics has announced technology deals with Nuron Biotech (TheraPEG), Celtic Pharma (TheraPEG), Spirogen (ThioBridge), MacroGenics (ThioBridge), and Antitope s Composite Human Antibodies and Composite Proteins technology has been used to create products in development by, among others, Opsona, Kolltan, NasVax and Therapure. Antitope: Babraham Research Campus Babraham Cambridge CB22 0AT UK +44 (0) john.burt@polytherics.com info@polytherics.com 2001 John Burt, CEO Matthew Baker, CSO Sally Waterman, COO Julian Smith, CFO

90 CONTACT Pascale Malgouyres Chief Business Officer 200, Avenue Jean JAURES LYON FRANCE POXEL 1st round : Me 16 2nd round : Me 13 POXEL operates independently as a lean organization with strong in-house drug development expertise. POXEL pipeline consists in innovative projects with new mechanisms of action, with an activity on glucose metabolism, other cardiovascular risk factors and with an improved safety profile compared to currently available therapies. Key features of the company: Imeglimin, 1st in-class oral antudiabetic agent, having already achieved its clinical proof of concept. Excellent benefit/risk ratio. A direct AMPK activiator program with a lead close to first-in-man. 4 other innovative programs in early stage development Strong IP position Seasoned team of executives coming from the Pharma Industry Network of re-known international key opinion leaders, experts and suppliers +33 (0) (0) Thomas Kuhn, CEO Pascale Malgouyres, CBO Pascale Fouqueray, CMO Sebastien Bolze, CSO Eric Massou, CFO Sophie Bozec, VP Diabetes R&D

91 CONTACT Dr Christoph Burdack, CSO Priaxon AG Gmunder Str a D München +49-(0) Priaxon AG Capital structure: 56% held by one institutional investor 32% held by Founders Priaxon AG, based in Munich, Germany, is a drug discovery and development company focused on developing small molecule therapeutics against hard-to-drug protein-protein interaction targets, using a unique, proprietary technology platform PriaXplore. Priaxon has already made two big pharma license/collaboration deals, one with Boehringer Ingelheim and one with GlaxoSmithKline, validating Priaxon s proprietary technology platform for PPI drug discovery. With the recently founded subsidiary, Priaxon Inc., at the world-renowned Fox Chase Cancer Center in Philadelphia, United States, Priaxon has now an additional access to all the high class assays and novel promising targets in oncology, which significantly strengthens its drug discovery efforts in oncology by adding world-class biology capabilities to complement Priaxon s world-leading chemistry technology. Priaxon has focused on partnering projects at an early stage so far and decided now to develop selected inhouse oncology projects on its own to later stages incorporating a higher level of value added. So the business model is based on the goal to maximize value and minimize the risk in drug discovery by both retaining selected projects in-house and establishing multiple licensing deals. +49-(0) burdack@priaxon.de 2008 Dr Christoph Burdack, CSO Christoph Burdack studied chemistry at the Technical University of Munich. He specialized in organic chemistry with the focus on new Multicomponent Reactions and earned his PhD in the group of Prof. Ivar Ugi, one of the fathers of Multicomponent chemistry. In 2001 he founded the Priaton GmbH, a company for medicinal chemistry and drug discovery services. He remained in the company until 2007 as a managing director. From 2008 he worked as a consultant for various Biotech companies. Since 2009 he has been CSO of Priaxon AG.

92 CONTACT Hendrik Liebers CFO Weinbergweg 22 D Halle (Saale) Germany Probiodrug Probiodrug has developed a novel therapeutic approach against Alzheimer s Disease (AD), based on inhibiting the enzyme Glutaminyl Cyclase (QC). In AD, QC catalyzes the formation of the pyroglutamic versions of amyloid beta (pgluabeta) species with increased neurotoxicity, prolonged half-life and increased aggregation propensity. They account for about 50% of the whole ABeta deposited in the typical AD plaques. Inhibition of QC in several AD animal models has been shown to reduce pgluabeta and improve cognitive abilities. The main program is paralleled by an anti pgluabeta antibody approach. Probiodrug is private and backed by major institutional and pharma investors. Dr Konrad Glund, CEO Hendrik Liebers. CFO Dr Inge Lues, CDO Dr Ronald Black, CMO 1997

93 CONTACT Eric Halioua Co-founder and CEO Promethera Biosciences Watson & Crick Hill Rue Granbonpré, 11 B-1435 Mont-Saint-Guibert Belgium Promethera Biosciences Promethera Biosciences has been funded by Venture Capital and grant and loand from the Walloon region (Belgium) since 2009 and a total of 34M Euros has been invested through two rounds of financing. Promethera Biosciences has completed in March 2012 a second financial round (B-Round) of 23.6 million euros (~USD 31.4 million). Promethera Biosciences is a pharmaceutical company that develops innovative therapies for the treatment of liver disease. It is currently developing two products based on a newly discovered and patented cell, the Heterologous Human Adult Liver Progenitor Cells (HHALPC): Promethera HepaStem is a cell therapy product based on the use of allogeneic stem cells isolated from healthy adult human livers (Heterologous Human Adult Liver Progenitor Cells, HHALPC). These cells can be used to treat a wide variety of liver diseases, from rare inborn metabolic diseases (which can be classified as orphan diseases and mainly affect children), to acquired deficiencies affecting adults, such as fulminant hepatitis or liver fibrosis. This treatment has already received the orphan drug designation from the European Medicines Agency for the treatment of two very debilitating paediatric pathologies and from the Food and Drug Administration (USA) for boths indications. Promethera HepaScreen is a different, non-therapeutic product that uses the same adult human liverderived stem cells as a biotechnology tool designed for evaluation of new chemical entities. This product meets a real need in the market, which currently lacks sufficiently predictive models to assess the hepatic metabolism of chemical compounds in the body. This unique cell model will be made available to the pharmaceutical industry to evaluate the metabolism and toxicity of new drugs in humans in a more reliable way than animal experimentation, thereby reducing the need and number of animals for such experiments. The company is a spin-off of the Université Catholique de Louvain (UCL), founded in 2009 by Professor Etienne Sokal and Eric Halioua, CEO of the company. Promethera Biosciences has 45 employees led by an experienced management team Eric.halioua@promethera.com 2009 Mr Eric Halioua, Chief Executive Officer Dr Béatrice De Vos, Chief Medical Officer Mr Philip Parkinson, Chief Financial Officer Mr Claude Dedry, COO Prof Etienne Sokal, Chief Scientific Officer Dr Carole Monterrat, VP Business Development

94 CONTACTS Dr Marion Kauth CEO Dr Michael Ruppert Director Business Development Ms Andrea Patzer Management Assistant Protectimmun GmbH Raised seed capital: e 1.7 M Sales 2013 (exp): e 0 EBIT 2012: e Employees: 4 Capital demand: e 5.0 M Intended use: Production of clinical batch material and conduct of early clinical trials (Phase I and II) in Ückendorfer Straße 237e Gelsenkirchen Germany Protectimmun is a pharmaceutical R&D company developing inno-vative drugs in the field of allergic and chronic-inflammatory airway diseases. The product develop-ment is based on natural sub-stances and specific bacteria that were identified in particular farm environments based on compre-hensive epidemiological studies. As its lead project, Protectimmun develops a first-in-class primary intranasal allergy-prophylaxis to induce long-time protection from hay fever and allergic asthma in early life. Start of clini-cal phase is scheduled for USP: Primary prevention from allergic sensitization against aero-allergens by application of probi-otic bacteria via the nasal mucosa. First-in-class develop ment, no direct competition. Market: Target population are all healthy infants in the first year of life resulting in 5 million newborns eligible for treatment each year in EU and US; 1.5 million thereof with an increased allergy risk due to allergic parents. There is a high unmet medical need due to the increasing prevalence in allergic diseases. Establishment as standard therapy (such as recom mended vaccines) is envisaged. Peek sales expecta-tions exceed EUR 1 bn. per year in EU and US. Business model: Development up to clinical proof-of-concept. Licensing to an established pharma-ceutical company and revenues from milestone payments and royalties. +49 (0) (0) m.kauth@protectimmun.de 2007 Dr M. Kauth, Chief Executive Officer Biologist & business economist, more than 15 years of experi-ence in research & industry Prof Dr A. Bufe, Advisor & Co-founder Head of Experimental Pneu-mology Ruhr-University Bo-chum, paediatrician, more than 20 years expertise in allergology including clinical trials Dr M. Ruppert, Business Development Biologist & MBA, more than 15 years of experience in Pharma-/Biotech industry

95 CONTACT Dr David E. Reese President/Chief Executive Officer 160 Varick St, Suite 1101a New York NY Provista Diagnostics, Inc. FINANCING Series A Preferred: $4.95MM Feb 2012 $2.55MM Sep 2012 $6.00MM Mar (E) EBIT (3,349,776) (1,200,000) Current Assets 1,527,339 2,200,000 Current Liabilities 340, ,000 Capital Exp. 529, ,000 Tel Cell reesed@provistadx.com 2010 Provista Diagnostics, Inc. is a privately held molecular diagnostics company focused on developing and commercializing through its dtectdx platform, proprietary diagnostic, prognostic and predictive tests for cancers affecting women, including breast, endometrial and ovarian. Provista also offers diagnostic testing and clinical laboratory services to the pharmaceutical and biotechnology industries through Provista Diagnostics Reference Laboratory (PDxRL), a CLIA-accredited and GLP capable laboratory, licensed in 49 states to perform human clinical testing. Dr David E. Reese, PhD, President/Chief Executive Officer Joseph Cooper, Chief Operational Officer John Fermanis, Chief Financial Officer Joseph Eggler, Chief Commercial Officer Sherri Borman, Ph.D., HCLD/CC (ABB), Laboratory Director, Vice President of Laboratory Operations

96 CONTACT Nadine Rahmani Executive Assistant SENSORION SAS Le bruyère 2000 (bat 2) Zone le Millénaire 650 rue Henri Becquerel MONTPELLIER France +33 (0) Sensorion Funding to date: e4m + non-dilutive grants Sensorion is a private specialty company dedicated to the development of new drug treatments for the inner ear, vestibular and cochlear, disorders. On the basis of academic research developed at INSERM, Sensorion selected several clinically validated targets and pathways of interest and consolidated a pharmacology-driven proprietary technology platform now used to study potential drug candidates. R&D activity aims at moving into clinical testing several firs-in-class programs at late pre-clinical stage and progress 2nd generation programs. Laurent Nguyen, MD, MPH, CEO +33(0) contact@sensorion-pharma.com 2009

97 CONTACT Dr André Rosenthal CEO Hermannswerder 20A Potsdam Germany Signature Diagnostics AG Seed round in 2004 C round in 2008 Follow-on C round 2010 Follow-on C round in million EUR raised so far Colorectal cancer molecular Dx company Develops blood-based and tumor tissue-based deep sequencing test for prognosis, prediction of response and monitoring. Company owns large prospective-ly collected tumor/plasma bank in colorectal cancer 40 hospitals in 8 German states are clinical partners for this biobank >8.000 patients with colorectal cancer of all four stages recruited Matched fresh-frozen, FFPE, and plasma samples with clinical data available for the vast majority of the patients Lead product is OncoDetect: Ultra-deep sequencing test of circulating free DNA (cfdna) in the plasma of patients with advanced colorectal cancer 10 colorectal cancer driver genes (49 amplicons)are deep sequenced Multiplexed test Test possess extremely high median coverage of fold for the 49 amplicons Detects mutations at low allele frequency Clinical application for OncoDetect Monitoring micro-metastasis in patients with stage III CRC Monitoring patients with metastatic colorectal cancer over time to detect new somatic mutations and changes of mutations frequencies under therapy Business opportunity Next generation sequencing (NGS) is presently focused on FFPE tumor tissue. NGS is used to determine the mutation status of key driver genes like KRAS, BRAF, EGFR and others at baseline (before treatment). Under treatment with chemotherapy or targeted drugs patients often develop resistance to the drug /drug combination. Resistance often occurs due to new mutations in driver gene. At present there is no way to monitor the mutation profile over time as tumor tissue is only available at the beginning of treatment. NGS of circulating free DNA (cfdna) opens a new way to the monitoring of cancer patients. However, ultra-deep coverage is required to detect somatic mutations at low allele frequency. Monitoring patients with colorectal cancer is an indication of high medical need and offers an attractive new business opportunity as several tests per year can be done for each patient over a period of several years. Company owns CLIA lab in Germany and will start offering OncoDetect by the end of year to German and European market Company will seek partnerships with Dx and NGS companies for development and marketing OncoDetect in the US and Asia Dr André Rosenthal, CEO

98 CONTACT Evan A. Facher, PhD President & CEO Cedar Ave. Cleveland, OH SironRX Therapeutics, Inc. Series A Financing of $3.4M in August 2011 SironRX Therapeutics is a private clinical-stage company developing novel therapies for dermal wound repair with a specific focus on mitigating scar formation and accelerating wound healing. The company s lead product, JVS-100 is a clinically tested, non-viral DNA plasmid that encodes stromal cell-derived factor-1 (SDF-1). SDF-1 is naturally produced by the human body in response to tissue injury activating the body s own native repair processes through recruiting endogenous stem cells and other progenitor cells to the damaged region. SironRX is currently enrolling in a double-blind, placebo-controlled, randomized clinical trial for surgical wounds. The company is evaluating JVS-100 drug safety and its ability to reduce scar formation and accelerate wound repair. Previous clinical studies with JVS-100 have demonstrated the drug is well tolerated and safe. Evan A. Facher, President & CEO

99 CONTACTS Sören Schreiber Founder & CEO Soluventis GmbH Im Lottental Bochum Germany +49 (0) (0) Soluventis GmbH Financed with venture capital from a renowned single investor Soluventis is the future of therapeutic RNA interference The Soluventis-platform is based on the most powerful drug delivery system, an entirely new type of Nanocarrier characterized by incomparable high efficacy and a very good safety profile. The Soluventis Nanocarrier completely shields the transported active substances from blood and immune system contact and reaches reliable target organs including poorly vascularized tumor tissue. We have the capability to transport therapeutic sirna, microrna and peptides. The frozen Nanocarrier has a long shelf life in ampoules whereas on the other hand in the organism it is completely eliminated within one day. Soluventis has a portfolio of oncologic sirnas which significantly improve tumor reduction and elimination of metastases in comparison to standard chemotherapeutic agents. In combination with the novel drug delivery system we offer a faster and more effective development of innovative therapeutics for pharmaceutical companies. Soluventis stands for the development of innovative clinical candidates which promise a pronounced increase in life expectancy of patients. soeren.schreiber@soluventis.de 2009 Prof Dr Sören Schreiber, Founder and CEO Physician and Professor of Physiology with more than 15 years of experience as head of research projects Developed the Nanocarrier based on knowledge of the main components Dr Désirée Garten, Founder and Managing Director Physician and in the previous years postdoctoral Research Fellow Advancement of the Nanocarrier during the last years

100 CONTACTS Dr Raúl Insa Chief Executive Officer Dr Santiago Esteva Head Scientific Operations Barcelona Science Park Baldiri Reixac, Barcelona Spain / SOM Biotech Sources of Financing Founders: FFFs: VC firm: Institutional: Grants & loans: Investment in R&D Funding capital required: Funding application: To secure the two most advanced products to Phase IIa p.o.c. in humans. Expected sales: > 60MM in insa@sombiotech.com esteva@sombiotech.com 2009 SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new therapeutic indications for given drugs, which we are offering to partners for expanding their drug pipeline. During the last 3 years we have validated 41 new indications, with 18 positive hits (43%), of which 3 cover clear medical need indications: SOM0777 for the treatment of Glioma, already licensed to Argon Pharma. SOM0226 for the treatment of TTR-Amyloidosis. Orphan Disease. Phase II planned for 3Q SOM3355 for the treatment of Huntington Disease, Orphan indication. Phase II expected for 1Q more repurposing programs per year are running to file the advanced company pipeline. Raúl Insa, MD, PhD, MBA., Chief Executive Officer Joaquim Trias, PhD., Advisor & Member of the Board Ramon Morera, BS, MBA., Part-time Chief Financial Officer Núria Gavaldà, PhD., Chief Scientific Officer Núria Reig, PhD., Project Coordinator Oscar Huertas, BSc., Chief Technology Officer Santiago Esteva, PhD, Head Scientific Operations

101 CONTACTS Mats Grahn COO Ekaterina Medvedeva Marketing Director Spiber Technologies AB BMC, Husargatan 3 Box Uppsala Sweden info@spiber.se mats.grahn@spiber.se ekaterina.medvedeva@spiber.se Spiber Technologies AB A Company founded on the inventions of a new biomaterial: Functionalized recombinant spider silk for use in for example: Stem Cell Culture Wound Care Beta Cell Culture for diabetes treatments Regenerative Medicine Coating of implants Diagnostics sensitivity enhancement Monika Hagman, CEO, CFO Mats Grahn, COO Ekaterina Medvedeva, Marketing Kristina Martinell, Production My Hedhammar, R&D 2008

102 CONTACT Dr Claudia Ulbrich CEO Zeppelinstr Potsdam Germany t-cell Europe GmbH Capital raised to date: 1.45 Million EUR Additional capital sought: 5.5 Million EUR t-cell Europe GmbH, a spin-off of the Berlin Brandenburg Center for Regenerative Therapies (BCRT), is aiming to become global technology leader in the application of T-cell-based therapies used in transplantation medicine. Over the next few years, with its three proprietary platform technologies (PT), the company will develop and clinically validate novel T-cell-based products to regulate the immune system and treat viral infections. t-cell will then market these products gradually in a number of different indications in collaboration with strategic partners. Our company s lead reference product will be a first-in-class Treg cell product/therapy for kidney transplantation that suppresses organ rejection in recipients. The innovative approach, which is the first to promise a cure rather than simply ongoing treatment, will significantly improve quality of life for patients who currently have to take high-dose immunosuppressive therapies for the rest of their lives after receiving a donor kidney. t-cell Europe s technologies can be applied in a range of additional indications, which opens up huge opportunities for the company s growth and development. In the pursuit of these promising applications, the company has developed three technology platforms based on key patents and licenses that ensure exclusivity over the long term. info@t-cell.de 2010 Dr med Claudia Ulbrich, CEO Prof Dr med Petra Reinke, Chief Clinical Advisor Prof Dr med Hans-Dieter Volk, Chief Scientific Advisor

103 CONTACT Diederik Klaassen General Manager Smalle Haven EH Eindhoven The Netherlands TNC Bio First production and turnover in Product redesigned and successfully tested and reintroduced in 2013, first gmp production may New products to be introduced q4. Turnover is projected to be 10s of mlns in the coming years at a high margin. Angel funded 700k long + 400k short, seeking vc for second round. TNC Bio produces, markets and distributes XerumFree and XerumFree derived products. XerumFree is a fully defined, thus animal component free additive replacing e.g. fetal bovine serum, hydrolisates and other undefined components in cell culture. It is universal for most cell lines, primary cultures and stem cells. Due to its defined nature it is certified free of viruses and animal contamination, has a constant composition and reduces costs in testing and storage. There are no restrictions in production volumes and it is GMP produced. These revolutionary products focuss on the essence off cell growth and removing hurdles in production and regulatory affairs. XerumFree can be used as an additive to replace FBS but is also core to special growth kits (e.q. first serumfree HUVEC kit). The company focusses on big pharma, vaccine producers and advance therapeutics researchers and developers. The market currently dominated by fetal bovine serum is projected to grow from 1 Bln. to 5 Bln. USD in the coming 5 years, exceeding this year already the natural maximum of FBS supply (1 Bln.USD). T M dklaassen@tncbio.com 2011 Diederik Klaassen, General Manager distribution sales, finance, operations Maarten van Tiel, General Manager end user sales and science TBA, Chief Scientific Officer

104 CONTACT Dr Dirk Pelster COO Frankfurter Ring 193a München Germany TRION Pharma GmbH TRION Pharma is a privately held biopharmaceutical company that has established a novel approach to cancer immunotherapy. The trifunctional antibodies are based on a proprietary platform technology for which TRION has secured IP rights around the world. The company s unique family of trifunctional antibodies, called Triomab, simultaneously activates multiple immune defense mechanisms against cancer. As a result, tumor cells as well as cancer stem cells are specifically destroyed with hitherto unknown potency and precision. Moreover, trifunctional antibodies are able to induce anti-tumor immunity (i.e. a vaccination against the patient s individual tumor) and therefore combine passive with active immunization. Removab (catumaxomab), the most advanced candidate of the Triomab family, received market approval in EU, Russia, Canada and Israel for the intraperitoneal treatment of malignant ascites in patients with EpCAM positive carcinomas. Removab is the first approved multispecific antibody worldwide. Currently, three further Triomabs are in development: Rexomun/ertumaxomab (anti-her2 x anti-cd3), Lymphomun/Bi20 (anti-cd20 x anti-cd3) and Ektomun (anti-gd2 x anti-cd3) For more information please visit the company s website at Dirk.Pelster@trionpharma.de 1998 Dr Horst Lindhofer, CEO Dr Dirk Pelster, COO

105 CONTACT Holger Bock PhD CEO Mitterweg 24 A-6020 Innsbruck Austria ugichem GmbH Funding to date: e9.7m Investors: BioScience Venture Group, V+ investment fund, private investors The company is seeking new investors alongside existing shareholders for the closing of a new financing round of e10m in Q1/2014. ugichem is an Austrian privately held biotech company dedicated to the development of a new generation of antisense drugs. Based on its proprietary Ugimer platform, ugichem is developing innovative antisense drugs with a unique therapeutic efficacy profile for immune mediated inflammatory diseases (IMID) where existing therapies are insufficient or do not work. ugichem initially focuses on rheumatoid arthritis (RA) as lead indication. Antisense drugs are assessed to become the next major breakthrough in molecular medicine. The first product has entered the market and numerous new antisense drugs are currently in clinical development. However, the standard, RNA based, antisense concepts have failed so far in the IMID field. The reasons are insufficient activity in immune system relevant organs and cells in combination with unspecific immune system stimulation. Ugimers are non RNA based antisense drugs with a unique combination of delivery, efficacy and safety parameters confirmed to provide a new and more specific therapeutic efficacy profile for immune mediated inflammatory diseases with high medical need. Holger Bock PhD, CEO Thomas Lindhorst PhD, CSO Jürgen Soutschek PhD, CTO

106 CONTACTS Presenter: Jonas Hansson CEO Contact: Tanya Syed Project Manager Wilson Therapeutics AB Västra trädgårdsgatan 15 SE Stockholm Sweden Wilson Therapeutics AB Wilson Therapeutics AB, founded in 2012, is an orphan drug company focused on developing novel treatments for Wilson Disease (WD). Our lead compound, WTX101, is the proprietary salt of tetrathiomolybdate. Tetrathiomolybdate is a very strong and highly selective chelator of copper with proof of concept previously established in WD. Jonas Hansson, CEO David Clark, CMO Cecilia Wadell, Head of Clinical Operations Lars Olsson, Head of CMC Jonas.hansson@ofco.se 2012

107 CONTACT Dr Sonia Divney Manager, Director Route de Chenaux Grandvaux Switzerland divneyswiss@zarzatech.com Zarzatech Europe Sarl Private Funding. 1. Specialized pharmaceutical company focus on the development of niche products for the treatment of Oral inflammatory diseases. We collaborate with other Pharmaceutical and Oral care companies, as well as academic institutions across the world. (eg.it,col,us) 2. Our patented and lead products as medical devices are focus on the prevention of progression of Inflammatory diseases such as inflammation around teeth, medical devices or dental implants, skin and hospital acquired infections 3. Our background and experience is based on our s team experience in oral inflammatory diseases, intervention targets, host modulators and localized delivery of antibacterials. 4. Our partnerships and collaborations are with experienced teams in localized oral formulations, pre-clinical, invitro research institutions and our global ongoing collaborations with local distributors around the world. Our business strategies are focus on bringing pharmaceutical and medical device products to the market in a short time and with a low cost in development Dr Sonia Divney, Director, Manager, Founder Massimo Radaelli, President, Delegate

108 Supporting Organisations Bio Deutschland As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting and promoting the development of an innovative economic sector based on modern biosciences. The Berlin-based association currently has over 300 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies, as well as directors of BioRegions. This committee comprehensively represents the various fields in the sector. The member companies and their experts are organised in working groups that deal with the following topics: finance and taxation; licences and technical contracts; regulatory matters; innovation and entrepreneurship; HR; German-US cooperation; health policy; competition and regulatory policy; technology transfer; and PR. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises. BIO Deutschland is Germany s biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction. BIO Deutschland Am Weidendamm 1a Berlin Tel: Fax: info@biodeutschland.org

109 Supporting Organisations Biotechgate Your source for life science companies and licensing information. If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems - and even more.

110 Supporting Organisations BioTOP Berlin-Brandenburg BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region. It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster. The services provided by BioTOP include: Technology transfer science - industry Initiation and support of networks Support for technology-oriented start-ups Funding support for innovative projects Providing information on biotechnology Building and coordination of scientific and interdisciplinary networks Establishing contacts between experts from all disciplines Design and organization of events Public relations work for the biotech region Berlin-Brandenburg For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at Dr. Kai Bindseil BioTOP Berlin-Brandenburg Fasanenstr Berlin - Germany Tel: Fax

111 Supporting Organisations Citigate Dewe Rogerson Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company s overall strength and from the cross-fertilisation of ideas across sectors. The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. Citigate s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - 52 million), Algeta (Oslo Stock Exchange - 30 million), Santhera Pharmaceuticals (SWX CH88.5 million), ThromboGenics (Euronext Brussels - 35 million), Hutchison China MediTech (AIM - 40 million), Zentiva (LSE and PSE US $211 million), Arpida (SWX - 63 million), Inion (LSE - 35 million), TopoTarget (CSE - 30 million), BioFusion (AIM million) and ExonHit (Alternext million). Citigate Dewe Rogerson 3 London Wall Buildings London Wall London EC2M 5SY Tel: +44 (0)

112 Life Sciences Supporting Organisations College Hill College Hill Life Sciences provides a full service communications consultancy focused on science-based sectors. Within the life science field we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services). London Sue Charles The Registry, Royal Mint Court, London EC3N 4QN, UK T: +44 (0) F: +44 (0) lsinfo@collegehill.com Manchester Dr Eileen Paul / Chris Fisher Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK Tel: +44 (0) Fax: +44 (0) lsinfo@collegehill.com Munich Dr Douglas Pretsell Augustenstraße 79, Munich, Germany Tel: +49 (0) Fax: +49 (0) lsinfo@collegehill.com San Francisco Erik Clausen 201 Spear Street, Suite 1100, San Francisco CA 94105, USA Tel: +1 (415) lsinfo@collegehill.com

113 Supporting Organisations FreeMind FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen. FreeMind s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist our clients in making non-dilutive funding a key tool in their long-term financial strategy. Tel: (617) Fax: (617) info@freemindconsultants.com Boston FreeMind Group 423 Brookline Ave. #124 Boston, MA Washington DC FreeMind Consultants 4094 Majestic lane # 269 Fairfax, VA Jerusalem FreeMind Group Hi - Tech Center Hebrew University Jerusalem Israel

114 Supporting Organisations Going Public Media AG Founded in 1998, Going Public Media AG is one of the leading specialist magazine publishers about corporate finance, technology, investment / stock market. The Group publishes more than 100 journal issues annually and operates 10 sites in conjunction with print magazines and online formats. GoingPublic Media AG Hofmannstr. 7a München Tel.: Fax:

115 Supporting Organisations Life Science Austria Life Science Austria LISA is a program acting as a hub for people from all over the world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria. Working with all existing life science clusters in the Austrian regions ecoplus, human. technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy commercial development. Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ). Austria Wirtschaftsservice Gesellschaft mbh, Ungargasse 37, 1030 Wien, Austria Tel.: +43 (1) Fax: +43 (1) office@awsg.at

116 MC SERVICES Supporting Organisations MC Services AG MC Services AG, based in Munich and Duesseldorf, is an international Public Relations and Investor Relations firm specializing in life sciences. The Company s long-standing clients include leading, international public and private companies as well as venture capitalists and investment firms. Established for many years as a link between industry and the financial markets, MC Services provides comprehensive services in the fields of IR, PR, financial reporting as well as capital and corporate transactions. We leverage our extensive network in the international financial community and in the industry in a targeted way for the benefit of our clients in order to best prepare for financing rounds by means of qualified investor relations and media work, for example, or to visibly position our clients and their successes in the German and international finance, economic and trade media. Anne Hennecke (Managing Partner) Raimund Gabriel (Managing Partner) Tel: Fax: raimund.gabriel@mc-services.eu MC Services AG Schubertstraße Munich Germany

117 Supporting Organisations Swiss Biotech Association SwissBiotech One Nation One Biotech Cluster Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services. The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. Swiss Biotechs mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process. Further inquiries: SwissBiotech, Executive Office Tel. +41 (0) info@swissbiotech.org

118 Supporting Organisations Tiberend Strategic Advisors, Inc. Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies. 1. To enhance valuation 2. To build visibility for partnerships and strategic alliances Tiberend Strategic Advisors, Inc. 35 W. 35th Street, 5th Floor, New York, NY Tel: Fax: Fax

119 Supporting Organisations Torreya Partners LLC Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco.

120 Supporting Organisations Venture Valuation Venture Valuation specializes in independent assessment and valuation of technologydriven companies in growth industries, such as the Life Sciences (Biotech, Pharma, Medtech), ICT, high-tech, Nanotech, Cleantech and Renewable energy. In addition to valuation products, Venture Valuation offers high-quality, focused information services. Through our focus and unique position, we strive to fulfill and surpass our customer needs and add value to the partnership. Clients include investors, companies and development agencies. Venture Valuation AG Kasernenstrasse 11 CH-8004 Zurich Switzerland Phone: +41 (43) Fax: +41 (43)

121 Organisers Sachs Associates Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging markets conferences in association with major exchanges and news agencies. Sachs Associates is dedicated to the highest quality standards in conferencing and, as a result, produces only a limited number of events each year. Sachs Associates investment conferences focus on Emerging Markets, European Equities and Technology, and are held in major financial centres such as London, New York and Zurich. Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions. The benefits of conference participation with Sachs Associates may be summarised as follows: Multimedia Exposure Sachs Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well focused electronic and print media. Regular extensive coverage of all the Company s conferences is carried out through video streaming and extensive events coverage through major international financial news agencies, including Bloomberg, Dow Jones and Reuters. In addition, Sachs Associates has a number of long established relationships with other financial press organisations globally, which allow further effective distribution on behalf of its clients. Eminent Speakers Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the Company has attracted very senior political and economic personalities as speakers at its events. Sponsorship and Marketing Opportunities for forthcoming events Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market. Sponsorship of any of our events allows you to raise your company s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events. The following sponsorship and marketing opportunities are available at future conferences: Conference Sponsor including workshops and social events Exhibition stands Distribution of Promotional Material If your company is interested in exhibiting or sponsorship opportunities please call Sian Rodgers on WELCOME PHARMA LICENSING GROUPS SPEAKERS